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VALIDITY OF SELF-REPORT WITH RESPECT TO PRESCRIPTION
MEDICATIONS AMONG PREGNANT WOMEN
By
Pallavi Jaiswal
B.Pharm., Indraprastha University, 2007
M.S., Pharmaceutical Sciences, 2010

ABSTRACT
Objectives: Accuracy of self-report regarding prescription medication use among
pregnant women is largely unknown. Accurate self-reported information is needed for
medication reconciliation purposes, clinical management, clinical teratology research,
and monitoring of adherence. This study examined the accuracy of self-reported
medication use by pregnant women for medications used chronically and episodically or
intermittently during pregnancy. Further, predictors of inaccurate reporting regarding
prescription medication use were also estimated.
Methods: A cross-sectional analysis of data collected through the University of New
Mexico (UNM) cohort study, “Safety of Medication and Perception of Teratogenicity”
(SMART) was conducted. Pregnant women were recruited from UNM prenatal care
clinics and were asked to report all medications they took since their last menstrual
period. The analysis was limited to women enrolled in the first year of the study who had
at least one prescription for diabetes or opioid analgesics medications (representative of
chronic and acute medication use, respectively). The accuracy of agreement between self-
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report and medical records for each medication class was estimated by simple (κ) and
prevalence and bias adjusted (PABAK) kappa. Information from the medical records was
used as the „gold-standard‟. Multivariable logistic regression analyses were used to
determine predictors of inaccurate reporting of prescription medication use in this cohort.
Results: A total of 92 pregnant women were included in the analysis. Agreement for
diabetes medications was near perfect (κ=0.87; PABAK=0.91); whereas poor-tomoderate concordance was observed for opioid analgesics (κ=0.29; PABAK=0.57).
Among antidiabetic medications, concordance was highest for biguanides (κ=0.90;
PABAK=0.93) and lowest for sulfonylureas (κ=0.83; PABAK=0.87); whereas among
opioid analgesics, highest agreement was observed for strong agonists (κ=0.51;
PABAK=0.56) and lowest for moderate/low agonists (κ=0.06; PABAK=0.59).Women
engaging in at least one episode of binge drinking were found to be inaccurate reporters
of medication regarding prescription medication use (OR: 3.40, 95% CI: 1.13;10.29).
Conclusions: This study suggests poor accuracy of self-report with respect to
prescription medications used as short courses or intermittently during pregnancy.
Therefore, in clinical studies assessing safety of such medications in pregnancy, selfreported information needs to be supplemented by other sources. Accuracy of self-report
for medications used chronically is acceptable.
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CHAPTER – 1 INTRODUCTION

1.1 Prescription medication use during pregnancy
Prescription medication use during pregnancy in the United States is fairly high
[1, 2]. Estimates put the proportion of pregnant women taking at least one prescription
medication (excluding vitamin and iron preparations) during pregnancy in the range 5680% [2, 3], and approximately 32% pregnant women on an average use two prescription
medications during pregnancy [2, 4, 5].
Researchers have indicated that about 40-60% pregnant women are prescribed
prescription medications with unknown safety profile during pregnancy [2, 6]. Also,
given the high rate of unintended pregnancies (49%) in the U.S. [7], many women might
have accidental exposure in the early weeks of pregnancy to potentially teratogenic
medications before realizing that they are pregnant [7]. Such high rates are therefore
alarming when one considers the risk of accidental exposure to these medications and the
associated risks [7]. Hence, during pregnancy it is vital that accurate information about
medications and their risks is made accessible to both the patient and the physician.
In the United States, the Food and Drug Administration (FDA) has established a
classification system that assigns a letter category to medications on the basis of potential
to cause birth defects/teratogenic effects, ranging from class A (classified as being
relatively „safe‟ for use during pregnancy), to class X (classified as being contraindicated
for use during pregnancy, because evidence of potential risk posed by the medication
outweigh the possible benefits) [8]. Table 1 lists the above mentioned risk classification
system.
1

Table 1: The U.S. Food and Drug Administration (FDA) teratogenic risk categories
[8]
Category
Description
A

Controlled studies in women fail to demonstrate a risk to the fetus in
the first trimester; possibility of fetal harm appears remote.

B

Either animal studies do not indicate a risk to the fetus, and there are
no controlled studies in women; or animal studies have shown an
adverse effect, but controlled studies in women failed to demonstrate a
risk.

C

Either animal studies indicate a fetal risk, and there are no controlled
studies in women; or studies in women and animals are not available.

D

There is positive evidence of fetal risk, but the benefits may be
acceptable despite the risk.

X

There is definite risk based on studies in animals or humans or based
on human experience, and the risk clearly outweighs any possible
benefit.

While, this classification provided by the FDA is widely used in interpreting the
risk of teratogenicity associated with prescription medications used during pregnancy, it
is also criticized as being ambiguous and misleading that can create confusion and
concern among pregnant women regarding medication use during pregnancy [1, 9].
Recently, FDA has proposed to make extensive changes to the existing classification
system to make it more clear and understandable [10, 11]. As a part of the proposed
change, the exiting system of classification would be eliminated. The new pregnancy
labeling for medications would contain three sections: risk summary, clinical
considerations and data section [10, 11]. The risk summary section would classify the
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likelihood of the drug causing various birth defects [10, 11]. Clinical considerations
section would contain detailed information about prescribing decisions for pregnant
women, dosing adjustments, and also information about inadvertent exposure to the
medication [10, 11]. Finally, the data section would describe whether the information is
from animal or human data, and will also describe that data in detail [10, 11]. The
proposed changes would allow a broader spectrum of data, such as pregnancy registry
data, to be included in the determination of potential maternal and fetal harm [10].

1.2 Self-reported information: importance and problems
Data collection through self-reports is the most common method of gathering
information in epidemiologic studies or surveys [12-17]. Self-reported information can be
collected through self-administered questionnaires, face-to-face interviews, or telephone
interviews. Information collected by this method can range from information about
general health status of the subjects, information regarding specific disease conditions,
behavioral and lifestyle characteristics, to information regarding prescription medication
use.
Information collected by self-report plays an essential part in research to estimate
prevalence of a disease, access to health care, health care delivery, preventive behaviors
and utilization of health care services [18]. Various surveys are conducted at the national
level, e.g., Behavioral Risk Factor Surveillance System (BRFSS), National Health and
Nutrition Examination Survey (NHANES), and National Health Interview Survey
(NHIS). Most of these national surveys, like NHANES, BRFSS, The National Hospital
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Ambulatory Medical Care Survey (NHAMCS), also contain information about
medication use from the respondents. Information derived from these surveys has been
helpful in research, public health planning, and developing polices, health/preventive
campaigns, and improving health care delivery and access to care [19].
Physicians also routinely obtain information from the patients regarding their
medication use and often rely on patient self-report [5]. Information about medication use
is a vital component for the success and completion of a treatment regime. This
information is essential for medication reconciliation purposes and also to individualize
medication therapy suited to the patients‟ needs [20]. Medication reconciliation, as
defined by the Institute of Healthcare Improvement (IHI), is the process of reviewing and
comparing a patient‟s complete medication profile and history [21]. It is performed in
order to provide accurate and correct medication to the patients, and to prevent
discrepancies in medical care by identifying sources of potential medication errors, such
as duplications, omissions, dosing errors, adverse drug reactions and potential drug
interactions [21, 22]. Examples of medication errors include misreading or miswriting a
prescription. An adverse drug reaction occurs in response to a drug which is noxious and
unintended and which occurs at doses normally used in man for prophylaxis, diagnosis,
or therapy of disease or for the modification of physiologic function [22]. Medication
errors that are stopped before harm can occur are called potential adverse drug event [22].
Such errors are usually found to occur at various points during medical care, such as, at
the time of admission to any health care facility, transfer within the facility, and at the
time of discharge [22].
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In the year 2005, The Joint Commission (formerly, the Joint Commission on
Accreditation of Healthcare Organizations; (JCAHO)) had announced medication
reconciliation to be one of the National Patient Safety Goals [21]. Even though
medication reconciliation is considered an important exercise in the process of providing
medical care, there is no standard procedure to perform it. Mostly, a multidisciplinary
approach, consisting of participation from physicians, nurses, and pharmacists is utilized
[23]. During the course of this study (i.e., in the year 2009), TJC required implementation
of a process for obtaining and documenting a complete list of the patient‟s current
medications upon the patient‟s admission to the organization and with the involvement of
the patient [23].
During pregnancy, medication safety is vital in the light of issues related to the
risk of teratogenicity. According to previous research, approximately 6.0-9.5% pregnant
women in the United States are at risk of exposure to medications with potential
teratogenic effects [7, 24]. Lo et al. also found that over a period of 20 years (1980-2000),
information regarding the safety of about 90% of the newly marketed drugs approved by
the FDA was insufficient with regard to safety profile in pregnancy [24].
Often times during pregnancy, women might have some illness (pre-existing or
developed during pregnancy), such as diabetes mellitus, hypertension, or other chronic
illnesses that might necessitate drug treatment [9, 24]. Poor control of maternal
conditions increases the risk of birth defects [2, 9, 25]. Moreover, sometimes women
misinterpret recommendations about the use of prescription medications during
pregnancy. For example, they might misinterpret recommendation that the use of a
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particular medication during pregnancy is not recommended due to potential safety
concerns [9]. It has also been documented that due to the lack of information about
teratogenic risk posed by some medications, women can overestimate the risk of
teratogenic effects [24]. As a result, such perception can result in unnecessary anxiety or
even a termination of pregnancy [24]. Thus, medication reconciliation in pregnant
women is of particular importance, given the potential teratogenic effect of some
medications and the need to optimize therapeutic management of underlying maternal
condition/s during pregnancy [24].

1.3 Self-report bias
It has been reported that several limitations are associated with self-reported
information. These can potentially arise from various information biases, like recall bias,
interviewer bias, and social desirability bias [13, 16, 17, 26-29]. Recall bias occurs when
the response of the respondents in a survey or interview is affected by limits of memory.
Moreover in retrospective studies, recall among study subjects with adverse outcomes
(cases) can be substantially different from recall of healthy participants (controls). This
would also result in recall bias. Interviewer bias takes place when the survey instrument
is not self-administered, in which case the researcher is familiar with the study hypothesis
that further can potentially influence the responses and their interpretation. Social
desirability bias is another type of response bias when the respondents intentionally give
responses in a socially acceptable or desirable manner. Such type of bias is mostly seen
when the respondents are asked sensitive questions which they might deem inappropriate
or uncomfortable to answer.
6

In the elderly population and in cohorts of patients with chronic illnesses, it has
been found that such response biases occur mostly due to limited memory such as,
forgetting the diagnosis, and presence of other comorbid conditions. In the case of
inaccurate reporting by pregnant women, it has been found that recall bias occurs because
pregnant women do not find episodic or acute events to be significant enough to report to
the physician as compared to chronic illnesses/conditions, or they might not be able to
recall them because they are already taking medication for other conditions [5, 30].
Maternal recall in this regard has also been found to be affected by history of adverse
perinatal outcome, with events and exposures that took place in a pregnancy associated
with any adverse perinatal outcomes being recalled more accurately than those events
that occurred in a normal pregnancy [3, 31]
There is also evidence of social desirability bias in self-reported information
provided by pregnant women. It has been documented that pregnant women are unwilling
to disclose information about certain conditions or medications because of social stigma
associated with those conditions or behaviors. This is seen commonly in situations when
pregnant women are taking medication for conditions such as depression, sexuallytransmitted disease or substance abuse; all of which can be perceived as negative in
society [16, 29]. Similar evidence is present for alcohol consumption during pregnancy.
Women have discomfort in revealing information about alcohol consumption during
pregnancy because of fear of social stigma. Such behavior is deemed inappropriate as it
can harm the developing fetus. Researchers have also indicated that because of rising
awareness about these risky behaviors during pregnancy (smoking, drug use, and alcohol
consumption), women might feel embarrassed while disclosing such information, which
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might suggest that they are not able to curb their addiction to such risky behaviors even
during pregnancy [32-35]. Lastly, with regard to prescription medication use pregnant
women might not want to disclose information regarding consumption of medications
belonging to a high risk category (Category D or X), as it might be considered negligent
behavior with respect to the safety of the fetus [25], especially in cases of inadvertent
exposure. Thus, self-reported information cannot be relied upon solely to make clinical
decisions, and ascertainment of the accuracy of such information is vital in the light of
drawbacks that it presents.

1.4 The concept of ‘gold-standard’ with respect to accuracy of medication use
Usually, the accuracy of self-reported data is determined by comparing it with
some other source of information, considered to be the „gold-standard‟. Often,
information recorded in patients‟ medical records is considered as the „gold standard‟.
However, one of the major limitations of such „gold-standard‟ is that it often does not
contain information about medications prescribed outside the clinic/hospital where the
patient is currently seeking care [36-38]. In addition, other limitations associated with
medical records include delayed and erratic recording, illegible handwriting of
physicians, non-documentation of medications taken from an outside provider, and very
limited information about lifestyle and behavioral characteristics [26, 36, 39]. All of these
can influence the quality of the information abstracted from the medical records.
Medical records are a good source of information for medical/illness history of a
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patient, since in most of the cases they are accompanied by results of diagnostic
procedures confirming the diagnosis of the condition. However, the same cannot be said
regarding information recorded in medical records about medication use, especially in
cases where this information is documented on the basis of self-report by the patient.
Such information can be misleading particularly in the cases of medications used for the
treatment of acute or episodic illnesses. This can be attributed to the fact that acute
illnesses do not continue for a long period of time. On the contrary, most chronic
illnesses have a well-defined diagnostic criterion, continue for a prolonged period of time
and often require regular medication use.
Alternatively, other sources of information can be used for ascertaining accuracy
of self-reported information, e.g., information on prescription fills obtained from
pharmacy databases [16, 28, 29], administrative prescription registries [40], and wherever
possible, biochemical tests, e.g., like serum/urine cotinine levels for estimating smoking
exposure [32, 33, 35, 41, 42] . Medical records and prescription databases are reported to
be the most reliable sources [43].

1.5 Validity of self-reported information among general population with respect to
chronic and acute conditions
In the general population, a number of studies have assessed the validity of selfreported information for a range of medical conditions and medication use [12-15, 18, 20,
36, 38, 44-53]. Agreement in previous studies has been found to vary by the study
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population (e.g., elderly, cohorts of patients diagnosed with a specific condition,
members of health plans having a specific medication use), specific disease/condition
under investigation and the analytic method used to assess validity [15, 48]. However,
despite these inconsistencies in the study population and study methodology, researchers
have reported that patients provide reliable information about chronic conditions in
comparison with acute conditions. Researchers attribute this differential recall to various
reasons ranging from variability in diagnostic criteria and severity of the condition to
frequency of patient-physician visits associated with some chronic conditions [12, 15, 26,
38, 54].
Similar evidence is present for accuracy of self-reported medication use.
Typically, researchers have noted a higher accuracy of recall for medications used
chronically in comparison with medications used as short-courses or episodically. This
variation in recall of medication use has largely been ascribed to difference in the
frequency and duration of medication use. In addition, researchers have also studied
predictors that influence recall of medication use. Age, educational status and recall
interval are the most commonly reported predictors.

1.6 Validity of self-reported information among pregnant women
While the accuracy of self-reported information regarding prescription
medications in the general population has been validated in numerous studies, accuracy
of self-reported information regarding prescription medication use among pregnant
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women is largely unknown. In addition, there is dearth of information about recall
accuracy among pregnant women regarding information about the prescription
medications they take for chronic and acute conditions during their pregnancy.
Although knowledge of teratogenic potential is a critical part of a drug‟s
benefit/risk profile, pregnant women are rarely included in clinical trial. There may be
inadvertent pregnancy exposures during clinical trials of new products, but available data
are usually insufficient to permit an adequately powered statistical analysis [25].
Consequently, when a drug is first marketed there are usually no human data on the
effects of in-utero drug exposure. The only data on fetal effects initially available in the
product labeling usually comes from animal reproductive toxicology studies [25]. Despite
the lack of information on the safety of drug use during pregnancy, most pregnant woman
likely would be exposed to drugs. Fetal exposure can occur before a woman knows she is
pregnant. Some women enter pregnancy with medical conditions that require continuing
drug therapy. New medical problems may develop during, or old ones may be
exacerbated by, pregnancy.
Since clinical trials in pregnant women are unethical due to a potential harm from
medication exposure to the developing fetus, observational studies are used to study the
safety of medications in pregnancy [25]. Observational studies often rely on self-reported
data or a combination of self-reported data with information from the medical or
pharmacy records to make conclusions about teratogenicity or safety of specific
medications.
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1.7 Significance of the study and specific aims
Approximately 56-80% pregnant women use prescription medication during
pregnancy [2, 3]. Most of these medications are used for reasons other than
supplementing the nutritional requirements during pregnancy, e.g., treatment of an
underlying or pre-existing condition. Diabetes is one such condition that affects
approximately 3-10% of pregnancies in the United States, of which 90% is gestational
diabetes and 8% is pre-existing [55]. Researchers also estimate that cases of gestational
diabetes are rising at an annual rate of 8% [56]. Using data from a nationally
representative sample of a cohort of pregnant women, Andrade et al. indicated that 7.9%
of pregnant women in the United States are prescribed antidiabetic medication, of which
1.4% used insulin preparations [2]. In different European populations, researchers have
estimated the prevalence of use of antidiabetic medications use to be in the range of 0.181.0% [43, 57, 58].
Analgesics are also prescribed frequently in pregnancy. In the above-mentioned
study, Andrade et al. estimated that about 33.9% of pregnant women are prescribed
opioid and nonopioid analgesics, of which 2.7% were prescribed codeine/guaifenesin
preparations [2]. Earlier, Bracken et al. in their study noted that 0.4% of 1,427 pregnant
women recruited from five hospitals in Connecticut were prescribed opioid analgesic
medication [59]. In another study Piper et al. estimated that in a cohort of 18, 886
pregnant women receiving Medicaid, 25.6% were prescribed codeine containing
preparations, and 4.0% were prescribed propoxyphene containing medications [4].
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Further, Glover et al. reported that in a cohort of 578 pregnant women attending rural
obstetric clinics in West Virginia, 5.0% reported use of prescription medications
containing codeine, and 3.3% reported use of medications containing oxycodone [5].
Prevalence of specific opioid analgesic medications among pregnant women in the
United States has been also been reported as 3.3% for oxycodone and 4% for
propoxyphene [4, 5].
While these numbers suggest that a significant proportion of pregnant women do
consume prescription medication during pregnancy, the key question is how many of
them disclose information about their use. This study thus aims to evaluate the extent of
agreement between self-reported information and information in the medical records
regarding prescription medication use in a cohort of pregnant women enrolled in the
“Safety of Medications During Pregnancy and Women‟s Perception of Teratogenic Risk
(SMART) study” at the University of New Mexico (UNM), Albuquerque. In addition, it
will also identify predictors of inaccurate reporting with respect to prescription
medication use among these pregnant women.
The central hypothesis for this study is that the accuracy of self-reported
information regarding prescription medications use among pregnant women is affected
by the type of illness/condition (chronic vs. acute). This central hypothesis would be
tested by the following specific aims:

Specific aim 1:
To compare the agreement between self-reported information and information in the
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medical records in a cohort of pregnant women enrolled in the UNM-based SMART
study cohort.
Research hypothesis 1:
Agreement between self-reported information and information in the medical records will
be greater for medications prescribed for chronic medical conditions (represented by
antidiabetic medication), compared with prescription medications given for acute medical
conditions (represented by opioid analgesics).

Specific aim 2:
To examine the predictors of inaccurate reporting in this UNM-based study cohort.
Research hypothesis 2:
Certain maternal demographic (age, educational level, marital status, insurance coverage,
ethnicity, place of birth, language), lifestyle (smoking status, alcohol use), maternal
medical and reproductive characteristics (number of chronic conditions, gestational age,
previous adverse perinatal outcomes, gravidity, parity) and participants‟ knowledge and
attitudes towards medication use in pregnancy will influence the likelihood of
disagreement between self-reported data and information in medical records.

The findings of the study would contribute to the limited knowledge that exists in
the literature about the extent of agreement on prescription medication use between self
report and medical records among pregnant women. Accurate self-reported information is
needed for medication reconciliation purposes, clinical management, clinical teratology
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research, and monitoring of adherence. Findings of this study would thus help healthcare
providers and researchers to identify pregnant women who are more likely to inaccurately
report information regarding their prescription medication use and also identify
therapeutic classes which are especially prone to inaccurate reporting.
The purpose of collecting and evaluating data on drug exposure during pregnancy
is to address whether a particular drug exposure increases the risk of abnormal fetal
development above the background rate. With respect to research in the field of safety of
medication in pregnancy, often self-report is the only method of obtaining information
regarding drug exposure. Therefore, the findings of the study would contribute towards
research on safety of medication use in pregnancy, which often relies on self-reported
information to ascertain exposure. Findings of this study will also help in identifying the
classes of medication which are at higher risk of being incorrectly reported by pregnant
women. Relying on patient self-report alone for those classes can lead to incorrect
estimation of medication exposure and erroneous assessment of teratogenicity.
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CHAPTER-2 LITERATURE REVIEW

This chapter will provide an overview of the literature related to various studies
that have assessed the extent of agreement and accuracy of recall between self-reported
information and information from the medical records and/or other sources. The literature
review is presented in two main sections: 1) assessment of agreement in the general
population; 2) assessment of agreement in pregnant women.

2.1 Assessment of agreement in the general population
This section contains studies that have been conducted in various populations
(non-pregnant) to assess the accuracy of recall and agreement. This section is divided into
three parts: 1) assessment of agreement by condition; 2) assessment of agreement for
prescription medication use; 3) predictors of recall and agreement. Table 2 presents a list
of published kappa values of various medical conditions and medication use among
general population.

Table 2: Accuracy of agreement for specific medical conditions and medication use:
overview of literature
Medical
Kappa statistic
References
conditions/medications

(κ)
MEDICAL CONDITIONS

Chronic conditions
Diabetes

0.72 - 0.94

Kreigsman et al. [12], Haapanen et al.
[13], Bush et al. [14], Okura et al.
[15], Simpson et al. [20], Tisnado et
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Medical

Kappa statistic

conditions/medications

(κ)

References

al. [26], Skinner et al. [48], Merkin et
al. [51], Iversen et al. [53], Leikauf et
al. [60], Brownson et al. [61], Corser
et al. [54], Martin et al. [62], Miller et
al. [63].
Hypertension

0.24 – 0.85

Kreigsman et al. [12], Haapanen et al.
[13], Okura et al. [15], Merkin et al.
[51], Iversen et al. [53], Young et al.
[64].

Asthma

0.43 – 0.78

Tisnado et al. [26], Iversen et al. [53],
Corser et al. [54].

Musculoskeletal disorders

0.07 – 0.54

Kriegsman et al. [12], Simpson et al.
[20], Skinner et al. [48], Goebeler et
al. [49], Boissonnault et al. [52],
Miller et al. [63]

Depression

0.11 – 0.40

Goebeler et al. [49], Leikauf et al.
[60], Kwon et al. [65].

Congestive Heart Failure

0.09 – 0.60

Okura et al. [15], Simpson et al. [20],

(CHF)

Merkin et al. [51], Corser et al. [54],
Miller et al. [63].

Myocardial Infarction (MI)

0.40 – 0.55

Merkin et al. [51], Young et al.[64].

0.24 – 0.43

Kriegsman et al. [12], Simpson et al.

Acute conditions
Peripheral vascular disease

[20], Corser et al. [54].
Lower back pain

0.33 – 0.54

Haapanen et al. [13], Skinner et al.
[48], Miller et al. [63].

Pneumonia

0.27 – 0.62

Boissonnault et al., Iversen et al. [53]

Duodenal/peptic ulcer

0.14 – 0.29

Smith et al., Corser et al. [54]

Hay fever/rhinitis

0.40

Iversen et al. [53]
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Medical

Kappa statistic

conditions/medications

(κ)

Shortness of breath

0.20

References

Tisnado et al [26].

MEDICATION USE
Medications for treatment of chronic conditions
Cardiovascular disease

0.60 - 0.97

Tisnado et al. [26], Sjahid et al. [66],

(CVD) medications

Brown et al. [67].

Specific classes of CVD
medications
Calcium channel blockers

0.91

Caskie et al. [68].

Beta-blockers

0.80 – 0.97

Caskie et al. [68], Sjahid et al. [66],
Tisnado et al. [26].

ACE inhibitors

0.90

Caskie et al. [68].

Statins

0.88

Glintborg et al. [39]

Nitrates

0.20 – 0.31

Sjahid et al. [66], Tisnado et al. [26].

Cardiac glycosides

0.77 – 0.97

Caskie et al. [68], Glintborg et al. [39]

Vasodilating agents

0.73

Caskie et al. [68].

Hypotensive agents

0.83

Caskie et al. [68].

Antidepressant medications

0.42 – 0.77

Paganini-Hill et al. [16], Tisnado et al.
[26], Caskie et al. [68], Haukka et al.
[69], Kwon et al. [65].

HRT medication

0.21 – 0.92

Tisnado et al. [26], Nielsen et al. [70],
Caskie et al. [68], Kropp et al. [71],
Løkkegaard et al. [72].

Antidiabetic medications
Specific classes
Insulin

0.60 – 0.78

Tisnado et al. [26], Nielsen et al. [70]

Sulfonylureas

0.60 – 0.93

Glintborg et al. [39], Tisnado et
al.[26].

Biguanides

0.60

Tisnado et al. [26].
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Medical

Kappa statistic

conditions/medications

(κ)

TZDs

0.60

References

Tisnado et al.[26].

Medications for treatment of acute conditions
Opioid analgesics

0.15 – 0.49

Caskie et al. [68], Nielsen et al. [70],
Tisnado et al. [26].

NSAIDs

0.30 – 0.63

Tisnado et al. [26], Nielsen et al. [70],
Caskie et al. [68], Kropp et al. [71],
Løkkegaard et al. [72].

Gastrointestinal agents

0.50 – 0.67

Westbrook et al. [36], Nielsen et al.
[70], Caskie et al. [68].

Musculoskeletal disorders

0.64 – 0. 96

Solomon et al. [50], Curtis et al. [73].

2.1.1 Assessment of agreement by condition
Studies conducted to evaluate agreement by condition, often focus on the ability
of the respondents to recall diagnoses of chronic conditions. Self-reported information in
such studies has been compared with a variety of sources considered to be the „goldstandard‟, ranging from medical records and pharmacy records to physician notes.
Accuracy of self-report in such cases is reported to vary by the study population,
methodology, and the specific condition in question [15, 51, 60].
Studies have also reported difference in recall and agreement according to the
diagnostic criteria of the condition. Researchers have consistently reported higher
agreement for chronic conditions like diabetes and hypertension. Agreement for diabetes
has been reported in the range κ= 0.72 to κ= 0.94 in different studies [12-15, 20, 26, 48,
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51, 53, 54, 60-64], whereas for hypertension it has been reported in the range κ= 0.24 to
κ= 0.85 [12, 13, 15, 51, 53, 64]. Studies have also reported agreement in the range 37%73% for self-report of diabetes [17, 62]. Agreement for asthma has been reported in the
range κ= 0.43 to κ= 0.78 [26, 53, 54]. Smith et al. reported 42% agreement for self-report
of asthma [17]. Such high level of agreement for these conditions has been ascribed to the
fact that these conditions have clear and well-defined diagnostic criteria that are easily
understood by the patients, and hence easily recalled [15, 26, 38]. Continuous care and
regular medication use is required to control these conditions that also helps in
facilitating recall [15, 26, 38]. In addition, frequent contact with the healthcare providers
upon diagnosis of such chronic conditions is also documented as one of the reasons that
assists in recall [15, 26, 38, 54, 60, 64].
In contrast, low-to-moderate agreement has been reported for conditions like
musculoskeletal disorders (κ=0.07 to κ=0.54) [12, 20, 48, 49, 52, 63], peripheral vascular
disease (κ=0.24 to κ=0.43) [12, 20, 54], depression (κ=0.11 to κ=0.40) [49, 60], lower
back pain (κ=0.33 to κ=0.54) [13, 48, 63], and claudication (impairment in walking)
(κ=0.30) [13]. Low agreement has also been documented for specific cardiovascular
diseases like, congestive heart failure (CHF) (κ=0.09 to κ=0.60) [15, 20, 51, 54, 63],
myocardial infarction (MI) (κ=0.40 to κ=0.55) [51, 64]. The low level of agreement
obtained for these conditions is largely attributed to the ambiguous and complex
diagnostic criteria for these conditions which is not easily understood by patients [15, 26,
48, 54, 60, 63]. Conditions like CHF and peripheral vascular disease have irregular,
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fluctuating and intermittent symptoms which further makes the recall of these conditions
difficult [20, 54]. Subjective nature of conditions like lower back pain and arthritis is also
reported as one of the reasons that attributes to lower agreement for these conditions, as
researchers have reported that these conditions are more often reported by patients as
compared to their documentation in the medical records [49, 54].
One of the main concerns expressed in the studies conducted to assess the
accuracy of agreement by condition, has been the variability of recall because of
difference by the condition (chronic vs. acute). Low-to-moderate agreement has been
documented for pneumonia (κ=0.27 to κ=0.62) [52, 53], and duodenal/peptic ulcer
(κ=0.14 to κ=0.29) [17, 54], hay fever/rhinitis (κ=0.40) [53], and shortness of breath
(0.20) [26]. Episodic nature of these conditions has been attributed to the lower recall
rates obtained for these conditions [17, 26, 38, 54].
Studies have also been conducted in cohorts of cancer patients to assess
agreement between self-reported information and information from medical records.
Their findings vary by report of type of screening test and cancer site. High agreement
has been documented for self-report of breast cancer (91%), prostate and lung cancer
(90% each), prostate-specific enzyme (PSA) test, sigmoidoscopy, and colonoscopy
(κ=0.40 to κ=0.80) [45, 46]. One interesting finding by Mukerji et al. in their cohort of
patients with neck and head cancer was that while reporting co-morbid conditions,
patients reported some chronic conditions more accurately (diabetes, κ=0.89 and stroke,
κ=0.77), than other (arthritis, κ=0.11) [47].
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Summary:
In summary, the results of the studies conducted to assess agreement for selfreport of various conditions have a high level of agreement for most chronic conditions
compared with acute conditions or those with sporadic/intermittent symptoms. Even in
the presence of other comorbid conditions, recall for a chronic condition was high.
Accuracy of recall also is also affected by the variability in diagnostic criteria of medical
conditions, which might lead the patient to misunderstand or misinterpret the diagnosis.
Conditions with well-defined diagnostic criteria are recalled more easily by patients than
those conditions with complex or ambiguous diagnostic criteria.

2.1.2 Assessment of agreement for prescription medication use
Studies conducted to assess agreement for self-reported prescription medication
use often focus on therapeutic classes used for treatment of chronic conditions e.g.,
cardiovascular diseases (CVD), diabetes, musculoskeletal disorders, and hormone
therapy (HRT).
In a study conducted in the Dutch population, Van den Brandt et al. found
moderate agreement (61.2%) for recall of medications used in the past over a period of
two years [29]. Moderate-to-high agreement has been recorded for CVD medication use
across various studies (κ=0.60 to κ=0.97) [26, 66, 67]. Researchers have attributed this
trend to the fact that these medications are taken regularly and for a long period of time,
and are more likely to be accurately recalled [29, 70].
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While overall agreement for self-reported use of any CVD medication was high
in these studies, it varied considerably when comparison was made across specific drug
classes. For example, Caskie et al. reported highest overall agreement for CVD drugs
(κ=0.83) among the ten drug categories (including antihistamines, anti-infectives,
autonomic drugs, blood formation and coagulation products, CVD drugs, electrolytic
drugs, eye-ear-nose-throat preparations, gastrointestinal drugs, hormonal drugs) [68].
However, there was marked variation in the agreement across various drug classes for
CVD medications (κ=0.91 for calcium channel blockers; κ=0.73 for vasodilating agents;
κ=0.77 for cardiac glycosides; κ=0.84 for beta-blockers; κ=0.90 for ACE inhibitors;
κ=0.83 for hypotensive agents) [68]. Glintborg et al. also reported high overall agreement
for CVD drug use, but upon analyzing agreement by drug class, they found higher
agreement for digoxin (κ=0.97) and slightly lower agreement for statins (κ=0.88) [39].
Similarly, Sjahid et al. reported high agreement for β-blockers in their study
(κ=0.97) and low agreement for nitrates (κ=0.31) [66]. Similar findings were reported by
Tisnado et al. who reported κ=0.80 for β- blockers and κ=0.20 for nitrates in their study
[26]. Researchers have noted that this variation in agreement across drug classes is more
likely due to the difference in the frequency and duration of medication use. For instance,
β- blockers are used regularly, while nitrates are used only when needed [26, 66].
Studies have reported agreement for self-reported use of other prescription
medications too. Agreement for gastrointestinal medication use was reported as moderate
in various studies (κ=0.50 to κ=.067) [36, 68, 70]. Van de Brandt et al. reported 48%
agreement for gastrointestinal drugs in their study [29].
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High agreement has been documented for medications used for musculoskeletal
disorders [50, 73]. In a cohort of patients with a diagnosis of rheumatoid arthritis (RA),
Solomon et al. obtained overall moderate agreement for self-report of glucocorticoid use
as compared to low agreement for disease-modifying antirheumatic drugs (DMARDs)
use, for the reason that the former are comparatively more commonly used [50].
Specifically, they found high agreement for RA medications being used currently (κ=0.96
for methotrexate and κ=0.92 for hydroxychloroquine), but relatively lower agreement for
RA medications used in the past (κ=0.13 for methotrexate and κ=0.35 for
hydroxychloroquine) [50]. The authors reasoned that lower agreement for past RA
medication use could be because the patients could not recall specific drug use [50]. In
another study, Curtis et al. also reported high agreement for osteoporosis medication use
in a cohort of glucocorticoid users, ranging from κ=0.80 (for alendronate), to κ=0.64 (for
calcitonin) [73].
Fair-to-substantial agreement has been reported for self-report of antidepressant
medication use (κ=0.42 to κ=0.77) [16, 26, 65, 68, 69]. Researchers have noted that
agreement for antidepressants is usually lower because of the discomfort or reluctance of
patients to report such medication use [16, 29, 70]. These findings illustrate the issue of
social-desirability bias in reporting the use of medications for psychological conditions
[16].
Many studies have also reported moderate-to-high agreement for HRT use
(κ=0.51 to κ=0.92) [26, 68, 70-72]. One study however, reported lower agreement
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(κ=0.21) for self-reported HRT use, by comparing self-report against data from
prescription database [16]. The authors ascribed this low agreement to the rationale that
the some pharmacies from where medicines were purchased were not covered by the
particular prescription database used in the study [16].
For prescription NSAID use, fair-to-moderate agreement has been reported in the
literature (κ=0.30 to κ=0.63) [26, 68, 70, 74]. Tisnado et al. reasoned that lower
agreement for NSAIDs use may be because for their short-term use [26]. West et al.
further analyzed the influence of recall interval and found that agreement for NSAID use
decreased with an increase in the recall interval [28]. They also found that the recall
interval also influences the agreement for recall of specific drug name [28]. They
reported that the name of NSAID medication used 2-3 years before the interview was
recalled more often than those used 7-11 years prior to the interview [28].
For self-reported opioid analgesic use, poor agreement has been reported in the
literature. Caskie et al. reported κ=0.15 for opioid analgesic use and attributed this to the
low prevalence of opioid analgesic users in their study population [68]. Tisnado et al. and
Nielsen et al. also reported low agreement for opioid analgesic use (κ=0.40 and κ=0.49
respectively) [26, 70]. Low agreement in these studies has been ascribed to the fact that
opioid analgesics are often used intermittently or short-term and, therefore, are not easily
recalled by patients [26, 70].
Substantial agreement for antidiabetic medications has been previously reported.
Studies have reported agreement for insulin in the range of κ=0.60 to κ=0.78 [26, 70].
Agreement for self-report of any oral hypoglycemic use has been previously reported as
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κ=0.75 [70]. Tisnado et al. reported agreement for various classes of oral hypoglycemics
as κ=0.60 for thiazolidinediones (TZDs), sulfonylurea and biguanides respectively [26].
However, Glintborg et al. reported a much higher agreement (κ=0.93) for sulfonylureas
in their study [39].
Summary:
In Summary, the findings of above-mentioned studies indicate that prescription
medications used for chronic conditions are recalled more accurately than medications
used for acute conditions or on a short-term basis. Also, agreement for prescription
medication use differs by the therapeutic class of medication in question.

2.1.3 Predictors that influence the accuracy of recall
Studies that assessed patient characteristics with regard to accuracy of self-report
reported that age, limited memory, fading cognitive ability, educational status, income,
health status, level of physical activity, and duration or severity of disease can affect the
accuracy of recall [15, 47, 75]. Mukerji et al. and Okura et al. have also reported that the
presence of other comorbid conditions can influence the level of agreement [15, 47].
Okura et al. and Merkin et al. noted that agreement for self-report of presence of a
comorbid condition is higher among females as compared to males [15, 47].
Most notable predictors for recall of prescription medication use reported in the
literature include duration of medication use and recall interval [28, 29, 68, 70, 76]. West
et al. noted that recall interval was a significant predictor of NSAID drug name recall.

26

Shorter recall interval was associated with higher recall of NSAID name and dose,
compared to a longer recall interval [28]. Nielsen et al. and Van den Brandt et al. also
reported that medications used for a longer period are better recalled [29, 70]. The Van
den Brandt study reported better recall of drugs used for longer duration (63.6%
agreement for drugs used for 24 months or longer; 65.9% agreement for cardiovascular
drugs used for 24 months or longer) as compared to drugs used for a relatively short
period of time, e.g., 59.0% for drugs used for 6-11.9 months and 48% agreement for
alimentary tract disorder medications [29]. Caskie et al. and Kelly et al. also reported
lower agreement for medications taken for less severe conditions as compared to those
taken for more serious conditions [68, 76].

2.2 Assessment of agreement in pregnant women
This section is divided into four parts: 1) accuracy of report for risky behavior
among pregnant women; 2) accuracy of report of pregnancy history and related events; 3)
accuracy of report for prescription medication use among pregnant women; 4) predictors
that influence accuracy of report among pregnant women.

2.2.1 Accuracy of report for risky behavior among pregnant women
Studies conducted among pregnant women to assess the accuracy of self-reported
information for risky behaviors, have mostly focused on smoking status and alcohol
consumption during pregnancy. Majority of the studies used serum/urine cotinine levels
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as the „gold-standard‟ to check the accuracy of self-report for nicotine use and medical
records for alcohol.
One of the main concerns conveyed by authors is significant inaccurate reporting
of information regarding risky behaviors by pregnant women. Ford et al. in their study
found that 19.2% pregnant women identified themselves as active smokers during
pregnancy, whereas results of the serum cotinine tests showed this proportion to be
31.3% [33]. In contrast, they found self-reported information given by pregnant women
regarding their smoking status before pregnancy to be accurate [33]. Further, Webb et al.
found that 73% of women in their study reported as not being an active smoker during
pregnancy. However, this could not be corroborated with their serum urine cotinine level,
which was more than the predetermined cut off (80 ng/ml) to identify active smokers
[32]. Furthermore, Britton et al. estimated that 34.7% of pregnant women in their study
inaccurately reported as being nonsmokers, while their urine cotinine levels indicated
otherwise [77]. These findings truly point towards the issue of social-desirability bias
among pregnant women while reporting information about smoking status.
Of particular concern are the findings of the study by Rice et al. in which they
observed a good agreement for smoking status (κ=0.80), whereas poor agreement
(κ=0.17) was found for alcohol use during pregnancy [78]. The authors based this low
agreement for alcohol use to the fact that alcohol use was not regularly recorded in the
medical records [78]. Similarly, Hessol et al. also found lower agreement for alcohol
consumption in a study conducted in a cohort of pregnant Latina women [79]. They
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estimated the kappa value (κ) for self-report of alcohol use during pregnancy to be 0.37
using medical records as the „gold-standard‟ [79].
However, findings of a few studies show that sometimes pregnant women do
provide accurate information about smoking and alcohol consumption. This was shown
in the study by Klebanoff et al. where the authors compared self-reported information
about smoking given by pregnant women, with their serum cotinine levels and found that
majority (87%) of pregnant women identified as active smokers during pregnancy,
provided accurate information (κ=0.83) [42]. In another study conducted in a cohort of
pregnant women participating in the NICHD Trial of Calcium for Pre-eclampsia
Prevention (CPEP), Klebanoff et al. found substantial agreement (κ=0.72) between selfreported information and serum and urine cotinine levels [35]. Yawn et al. also a reported
high agreement (κ=0.85, 93% agreement) for self-reported smoking during pregnancy
upon retrospective comparison with medical records [31].
In another study Fox et al. assessed reliability of self-reported information about
smoking status and alcohol consumption in a cohort of pregnant women participating in a
randomized clinical trial of smoking cessation [80]. They compared self-reported
information about smoking status and alcohol consumption prior to pregnancy that was
collected first at 15±3.8 weeks of gestation, and later in the eighth month of gestation. It
was compared with the thiocyanate levels from their saliva samples collected at the time
of the first interview [80]. The results of the study showed that the agreement for
smoking status was identical in both the intervention (κ=0.61) and the control group
(κ=0.56) of the trial [80]. Similar results were also obtained for alcohol consumption
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(κ=0.52 for intervention group and κ=0.55 for control group respectively) [80]. Authors
however suggested that awareness among the study participants regarding verification of
their self-reported information against their saliva samples might have influenced the
level of agreement in a favorable way [80].
Researchers have also used other sources of data to ascertain agreement for selfreported smoking and alcohol use. Ernhart et al. and Jacobson et al. used information
collected at two different points in time, i.e., during pregnancy and post-partum [34].
Ernhart et al. reported that most women under-reported the information about alcohol
consumption during pregnancy, i.e., they reported lower level of drinking when asked
during pregnancy compared to ascertainment 5 years after their pregnancy [34]. Jacobson
et al. in their study conducted in a cohort of black pregnant women to estimate accuracy
of reporting alcohol consumption, both during pregnancy and postpartum, have also
indicated lower levels of agreement for ascertainment during pregnancy [81]. The authors
suggested that this could be due the stigma associated with drinking during pregnancy
[81].

2.2.2 Accuracy of report for pregnancy history and related events
Studies have been conducted to explore the extent of agreement for maternal
recall of pregnancy related events, primarily in pregnant women considered to be in „high
risk‟ group for adverse perinatal outcomes. High agreement has been reported for recall
of previous live births [16, 82-84], previous pregnancies and miscarriages [16, 82-85].
Low agreement for self-report of complications during pregnancy has also been
documented [82, 86, 87].
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2.2.3 Accuracy of report for prescription medication use among pregnant women
Very few studies have been conducted to assess the agreement for prescription
medication use among pregnant women. Overall, poor-to-moderate agreement for
prescription medication use has been reported [30, 40, 85, 88].
Olesen et al. conducted a study in Denmark to assess agreement for prescription
medication use in a cohort of 2,041 pregnant women [40]. They used self-reported data
from interviews conducted first at 6-12 gestational weeks and later at 12-15 gestational
weeks, and compared these data with the information from a county prescription database
[40]. They reported higher recall rates for prescription drugs dispensed 30 days prior to
the interview (50%, 95% CI:43;46), compared with the drugs dispensed 120 days prior to
the interview (43%, 95% CI:40;46) [40]. They also found that women had a higher recall
for prescription medications used for treatment of chronic conditions (100% agreement
for insulin, thyroid drugs, antiepileptic, and cardiovascular drug use; 80% agreement for
antidepressant medication use, and 76% agreement for asthma medication use) as
compared to those used on a short-term basis (40% agreement for NSAID use; 35%
agreement for anti-infectives use, 47% for antacid use, and 59% agreement for
antihistamine use) [40].
Bryant et al. compared self-reported information about the types of medications
used (prescription medication, OTC medication and vitamins/supplements) and specific
short-term illnesses/conditions during pregnancy with medical records, in a cohort of 202
still-pregnant and post-partum women [30]. They obtained moderate agreement for
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prescription medication use during pregnancy (κ=0.48), but lower agreement for OTC
medication and vitamin/supplements use (κ=0.02 and κ=0.07 respectively) [30]. Further,
they noted that agreement was somewhat lower for episodic illnesses that occurred during
pregnancy, e.g., κ= 0.07 for flu and upper respiratory infection and κ= 0.11 for
nausea/vomiting [30]. These low levels of agreement obtained in this study were
attributed to the reason that pregnant women do not view short-term illnesses significant
enough to be reported to the physicians [30].
In another study de Jong et al. assessed agreement for specific classes of
prescription medications used in a cohort of 246 post-partum women. They compared
information about medication use that was collected at the time of the participants‟
prenatal visits and compared it with information collected retrospectively seven years
later [88]. Overall, the authors found moderate agreement (55%) for medications used
throughout pregnancy [88]. Specifically, they found that the agreement was highest for
medications used during labor and delivery (77%) [88]. Moreover, de Jong et al. also
reported higher agreement for medications for which a list of name of the drugs was
provided. This was also corroborated by Mitchell et al. who noted that recall is influenced
by the nature of question asked [89].

2.2.4 Predictors that influence accuracy of self- report among pregnant women
Various predictors that affect agreement for reporting risky behavior have been
documented, however very few predictors that influence accuracy of reporting
prescription medication use during pregnancy have been reported. Klebanoff et al.
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studied the effect of race and ethnicity on recall and reported that African-American
women provide more accurate information about smoking behavior than white women
(κ=0.90 and 0.80, respectively) [42]. Hessol et al. reported that Spanish speaking Latina
pregnant women in their study cohort were more likely to accurately report alcohol use
during pregnancy, compared with English speaking Latinas [79]. Jacobson et al. and
Ernhart et al. noted that history of alcohol abuse and maternal depression might influence
agreement for alcohol and drug use during pregnancy [34, 81]. Britton et al. have
reported that multigravidity, multiparty and number of smokers in a household can
influence the accuracy of reporting smoking status during pregnancy [77]. For
prescription medication use, recall interval and type of illness (chronic/acute) has been
reported to influence the rate of recall [30, 40].

2.3 Summary of the literature review
The existing literature both in general population and pregnant women provides
an insight into various factors that can potentially influence the self-reported information
provided by patients. Even though heterogeneity of study samples makes comparisons
across studies difficult, frequently or commonly used medications are recalled easily [28,
38, 50]. So are medications used for longer duration (chronically) [28, 70, 73], as
compared to medications that are “used when needed” or short-term/intermittently [66,
68, 70]. In patients with chronic diseases, recall accuracy is reported to be influenced by
the number of medications they are taking and also the presence of other underlying
conditions that they might have [29, 38]. In addition, perceived „chronicity‟ and
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„severity‟ of a condition also makes its recall easier, as conditions that patients identify as
having more severe effects on their lives and daily activities, are recalled accurately [12,
29, 38, 54].
Studies have demonstrated that recall of past medication use is also affected by
the nature of the question asked. Typically, agreement is higher when question about the
use of specific medication is asked for self-report than collecting this information through
an open-ended question [15, 26, 38, 48, 50, 70, 89, 90].
Studies have reported inconsistent results in assessing accuracy of risky behavior
during pregnancy. But there is substantial evidence that pregnant women are
uncomfortable in revealing information regarding smoking and alcohol use during
pregnancy, because of social stigma and disgrace attached to this behavior, as they are
considered inappropriate during pregnancy. They however report such behavior
accurately when asked retrospectively. Specifically in pregnant women, there is evidence
that recall accuracy regarding medication use might be influenced by the recall interval.

* Refer to Appendix 1 for detailed description of the studies mentioned above in a
tabular form.
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CHAPTER-3 STUDY METHODS
This chapter discusses the research design, study methodology, hypothesis testing,
and statistical analyses in detail.
3.1 Study design
The study was a cross-sectional analysis to assess the validity of self-reported
information provided by pregnant women on prescription drugs that they take during
pregnancy. This was achieved by comparing their self-reported information (obtained
through a standardized questionnaire) about prescription medication use relative to the
information present in their medical records (the „gold standard‟).
Since for the purposes of this validation study subjects were not followed up, a
cross-sectional study design was utilized. For the purposes of this study, the information
regarding prescription medication use derived from the patients‟ electronic medical
records, was assumed to be the „gold standard‟, as it is the most comprehensive source of
patients‟ medical information, including information regarding prescription medications
and various inpatient and outpatient records. Hence, comparison of responses of pregnant
women regarding their prescription medication use with the information in their
electronic medical records was the most appropriate way to assess the validity of the
information they give for their prescription medication use. Alternative approaches and
limitations of the „gold-standard‟ used, i.e., medical records are presented in the
Discussion section (Chapter-5).
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3.2 Self-reported data- the ‘SMART’ study
The study was conducted by utilizing data from The Safety of Medications
During Pregnancy and Women‟s Perception of Teratogenicity (SMART) study, an
ongoing prospective cohort study being conducted at the University of New Mexico
(UNM), Albuquerque. The SMART study was initiated to ascertain the safety of the most
common medications (prescription, OTC, herbal products, and dietary supplements). The
study also aims to determine perception of teratogenic risk (perceived hazard) of the
medications taken by the study participants, and also ascertain barriers of patient-provider
communication regarding medication use during pregnancy. The study is approved by
UNM Human Research Review Committee (HRRC).
Study participants for the SMART study were recruited from the UNM Main
Hospital (UNMH) and its five satellite clinics throughout the city of Albuquerque, New
Mexico. These satellite clinics are affiliated with the UNM Department of Obstetrics and
Gynecology (OB/GYN). Patients at these clinics seek preventive medicine, family
planning, prenatal and postnatal care and treatment for chronic diseases, e.g., diabetes
mellitus, hypertension.
Pregnant women attending these prenatal clinics were contacted by a healthcare
provider and their interest for participation in the study was sought. Pregnant women who
were ≥ 18 years old, and had no prenatal diagnosis indicating an abnormal pregnancy
were included in the study. Women were recruited at any time of gestation and were
willing to be interviewed in either English or Spanish. All the study participants gave a
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written informed consent. As of 11/05/09, of the 494 women approached for
participation, 406 agreed to participate, resulting in a participation rate of 82.4%. Lack of
interest and time constraints were the most common reasons cited to choose not to
participate.
Self-reported data
All the participants participated in a semi-structured interview (Appendix 2) of
about 20-25 minutes duration, in English or Spanish, depending on their preference of
language. These interviews were administered by a trained bilingual interviewer, who at
the time was a Ph.D. candidate in Anthropology at UNM. The participants also granted
permission to access their medical records and permission to contact them with a followup phone interview, if needed.
In the interview, the participants were asked to report all the prescription, overthe-counter (OTC), herbal products and dietary supplements that they took since their last
menstrual period (LMP). For ascertaining prescription medication use, the participants
were asked, “ Have you taken any medications prescribed by your doctor or any other
healthcare provider since your last menstrual period, even if you stopped taking them
once you knew you were pregnant?” They were also asked to indicate their perception of
teratogenicity about these medications on a 5-point Likert-type scale, where 1 indicated
„not likely to cause harm‟ and 5 indicated „very likely to cause harm‟. In addition,
participants were also asked about their knowledge and attitude towards medication use
during pregnancy, and the sources of information that they refer to. Additionally,
information on general demographic and lifestyle characteristics, medical and
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reproductive history, and any pregnancy complication/s was also collected. Collected
data were entered into an SPSS® database.

3.3 Electronic medical record review- The ‘Gold-Standard’
The SMART study database also contains information about subjects‟
prescription medication use, which is systematically abstracted from their electronic
medical profiles (PowerChart®, Cerner Corporation). The PowerChart® is an electronic
health record management system developed by the Cerner Corporation® and universally
used by all services of UNMH. The patients are identified by their Medical Record
Number (MRN) which is provided by the University of New Mexico Hospital (UNMH)
to abstract information regarding prescription medication use from PowerChart®.
The medications identified from the PowerChart® records were classified into the
drug classes of interest and then recorded into the database. One respondent could have
multiple medication use, thus information about multiple medications was recorded under
respective fields in the database. For example, if a patient reports a use of glyburide, it
will be recorded in the class “sulfonylurea” for diabetes medication. If the same patient
reported the use of codeine, it was recorded in the “moderate/low agonist” class for
opioid analgesics.
In the medication list of PowerChart®, medications were listed as either “ordered”
or “documented”. While “ordered” medications are those that are prescribed by a
physician at UNMH, “documented” medications are the ones that are reported by the
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patient during the medication reconciliation process, and not necessarily consist of
medications prescribed by a physician at UNMH. For the purposes of this study,
information about “ordered” prescription medications was abstracted from the
PowerChart®, given the higher accuracy of such entries.

3.4 Study population and sample selection
The study population consisted of the first 311 pregnant women enrolled in the
SMART study. For the selection of final study sample the following eligibility criteria
were used:
3.4.1 Eligibility criteria:
Inclusion criteria:
1. Pregnant women enrolled in the first year of the SMART study.
2. Women who had at least one prescription for medication for either diabetes or
opioid analgesics from a provider at UNMH or its affiliated clinics (List of
specific classes is provided in Table 3 and 4).
Exclusion criteria
1. Prescription of opioid analgesics for chronic illnesses or chronic pain (requiring
treatment/medication for three months or more) [91, 92].
Rationale for inclusion/exclusion criteria:
The first 311 pregnant women enrolled in the SMART study were chosen because
these women had complete data derived from both the SMART study questionnaire and
PowerChart®. Women having at least one prescription for diabetes or opioid analgesics
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were chosen because we were interested in checking the validity of self-report among
pregnant women in chronic conditions vs. acute conditions.

3.4.2 Definition of chronic medication use
The National Center for Health Statistics (NCHS) defines a chronic condition as
the one that cannot be prevented by vaccines or cured by medicines [91]. Chronic
conditions continue for long durations, usually lasting for more than three months and
require long term medication use [91, 92]. For the purposes of this study, the above
presented definition was used to classify the medication use as chronic or acute. Chronic
medication use was defined as the medication use lasting for 3 months or more, whereas
acute medication use was defined as use for short-term or episodic conditions. Diabetes
was the most common chronic condition in this population. Therefore, antidiabetic
medications were chosen to represent chronic medication use.
Analgesics can be given for acute/episodic (e.g., fever, inflammation, pain
resulting from headache or backache) or for chronic conditions (e.g., rheumatoid arthritis,
chronic migraine). Even though NSAIDs were the most widely used class of analgesics in
this population, they were not included in this study as they are mostly available as overthe-counter (OTC) products. Therefore, opioid analgesics given for acute or short-term
use (< 3 months) were chosen as they can be obtained only through prescription.
After identification of a drug class from the self-reported data and medical
records, prescription medication use was categorized into one of the classes considered in
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this study, i.e., antidiabetic medication and opioid analgesics. Detailed exposure
information for these prescription medications are as follows:
1. Diabetes medication (Table 3): Study participants taking prescription
medication from at least one of the four major classes of the diabetic medication
[8, 93].
2. Opioid analgesics (Table 4): Study participants taking prescription medication
from at least one of the four major classes of opioid analgesics [8, 93].

Table 3: Drug classes for antidiabetic medication
Drug class
FDA risk
Route of administration
classification
Parenteral (subcutaneous or
Insulin and its analogs
(injectables)
intravenous)
a. Lispro insulin solution
b. Insulin aspart
c. Insulin glulisine
d. Insulin glargine solution
e. Insulin detemir solution
Sulfonylureas

B
B
C
C
C

a. Tolbutamide
b. Glipizide
c. Glyburide
d. Glimepiride
Biguanides

C
C
C
C

a. Metformin
Thiazolidinediones (TZDs)

B

a. Pioglitazone
b. Rosiglitazone

C
C

Oral

Oral

Oral
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Table 4: Drug classes for opioid analgesics
Drug class
FDA risk
classification
Strong agonists
Alfentanil
Fentanyl
Heroin
Meperidine
Morphine
Oxycodone
Remifentanil
Sufentanil
Hydromorphone
Oxymorphone
Moderate/Low agonists
(available in combination with
acetaminophen)

C
C
B
B
C
B
C
C
B
B

Codiene
Propoxyphene
Hydrocodone
Mixed agonists-antagonists and
partial agonists

C
C
C

Butorphanol
Nalbuphine
Pentazocine
Other
Tramadol

C
B
C

Route of administration
Oral/parenteral
(intravenous)

Oral

Oral/parenteral
(intravenous)

Oral
C

The initial study population consisted of the first 311 women enrolled in the
SMART study. Records (questionnaire data) of one patient did not have information
regarding prescription medication use, as this patient had to leave midway during the
interview because she started experiencing labor pains. Therefore, this patient was
excluded from the study. 310 patients with complete records (both self-report and
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medical records) constituted the study sample. Electronic medical records of all the 310
patients were reviewed for ascertaining documentation of prescription medication use for
either antidiabetic medication or opioid analgesic medication. After the review process, a
total of 92 patients were found to have a “recorded” medication use either, in self-report
or in the electronic medical record. Women who did not answer an interview question
(missing data) were excluded from the corresponding analyses in which that information
was needed.
3.5 Study variables
The study variables, obtained from the database (including derived/dummy
variables) and used in the statistical analyses are described below:

Table 5: Study variables
VARIABLE NAME

Age

Educational level

Marital status

Insurance coverage

Ethnicity

Place of birth

Language

DESCRIPTION

CATEGORIES

Demographic variables
Maternal age at the time
18-23 years
of interview
24-29 years
30 years and above
Maternal educational
Less than high school
level at the time of
High school/GED
interview
College and above
Maternal marital status at Single, never married
the time of interview
Married/Living with partner
Separated/Divorced/Widowed
Type of insurance
No insurance
coverage at the time of
Have any insurance
interview
Maternal ethnicity
White, non-Hispanic
White, Hispanic
Others
Maternal place of birth
United States
(United States or outside
Outside United States
United States)
Primary language
English
Spanish
Other
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VARIABLE NAME

Smoking status

Binge drinking

Medication use during
pregnancy

Birth defects caused by
medications

Alcohol consumption
during pregnancy

Sought consultation
about safety of
medication

Chronic conditions
Gestational age
History of previous
adverse perinatal
outcome

Gravidity

Parity

DESCRIPTION

CATEGORIES

Lifestyle characteristics
Current maternal smoking Never smoked
status
Past smoker
Current smoker
Alcohol consumption of 4 Yes
or more drinks since LMP No
on a single occasion
Knowledge and attitude factors
Knowledge and attitude
Stop taking all the medications upon
towards medication use
recognition of pregnancy
during pregnancy
Continue with necessary medications
Continue taking all the medications
as needed
Knowledge about ability
Never
of medications taken
Sometimes
during pregnancy to cause Often
birth defects
Very Often
Always
Knowledge and attitude
Should abstain
towards alcohol
OK to consume some alcohol
consumption during
OK to drink wine/beer, but not hard
pregnancy
drinks
Knowledge and attitude
towards medications
Yes
currently prescribed
No
(during pregnancy)
Medical/Reproductive Factors
Presence of chronic
None
conditions
At least one
Gestational age at the
Less than 20 weeks
time of interview
More than 20 weeks
Adverse perinatal
Yes
outcomes before the
No
current pregnancy, e.g.,
miscarriage, ectopic
pregnancy, termination,
stillbirth
Number of times the
Primigravid
respondent has been
Multigravid
pregnant
Number of times the
Nulliparous
respondent has given live Parity more than one
births
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3.6 Data analysis
3.6.1 Outcome measure: agreement for self-reported prescription medication use
The primary outcome to be measured in this study was the extent of agreement
between the responses provided by pregnant women regarding their prescription
medications for chronic or acute use with the information present in their electronic
medical records. For this purpose the agreement was defined as the presence of
concordant responses about prescription medication use in self-report and medical
records. This is illustrated in Table 6.

Table 6: Representation of agreement/disagreement
Information about
Information about
prescription medication
prescription medication
from SELF-REPORT
from MEDICAL
RECORD
Yes
Yes
Yes
No
No
Yes

Outcome

Agreement
Disagreement
Disagreement

In this study, agreement for chronic medication use was represented by agreement
for antidiabetic medication use, and that for acute or short-term use, was represented by
agreement for opioid analgesic use. Agreement was measured by estimating a simple
kappa statistic (κ), prevalence-adjusted and bias-adjusted kappa (PABAK) and observed
proportion of agreement (Po) values.
For assessing agreement for self-reported prescription medication use of
antidiabetic medications, agreement was first assessed for the specific drug classes that it
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comprises of, as identified in Table 3. For this, simple kappa, PABAK and the observed
proportion of agreement values were calculated for each class. Thereafter, a commutative
value (mean value) was calculated for agreement of antidiabetic medication use.
Similarly, agreements for all the drug classes for opioid analgesics identified in Table 4
were calculated, followed by calculation of a mean value of agreement measures. This
mean value represented agreement for overall self-reported use of opioid analgesic
medication
Table 7 illustrates an example, whereby it is shown how the information
regarding self-reported prescription medication use and the information derived from the
medical records was recorded in the database. In this hypothetical example, patient#001
reports the use of glyburide (antidiabetic medication) in self-report. This is recorded in
the class „sulfonylurea-self-report‟ for diabetic medication use. If this same information is
corroborated from the PowerChart® medication profile of the patient, then it is reported in
„sulfonylurea-medical record‟ of the patient, and according to Table 6 the outcome is
agreement. In the case of patient#002, information from self-report regarding use of
opioid analgesic use is oxycodone. It is classified under the class „moderate opioid-selfreport‟, but in the medical records, this information is not present, hence according to
Table 6, it is counted as a disagreement. Since a patient can have multiple drug use,
patient #003 represents how such a case might look like, if a patient is reporting the use
of all the three medications.
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Table 7: Example showing representation of self-reported data and medical record
data in the database
Pat id Su SR Su MR In
In
Mo
Mo
O Su
O In
O Mo
SR
MR
SR
MR
001
002
003

1
0
1

1
0
0

0
0
1

0
0
1

0
1
1

0
0
1

1
0

1

0
1

Where, pat id= patient‟s id
1= Yes
0 = No
SR = Self-Report
MR = Medical Records
Su = Sulfonylurea
In = Insulin
Mo = Moderate
O = Outcome of interest, i.e., agreement on medication use; (1= agreement, 0=
disagreement)
Sample characteristics were summarized by descriptive statistics. Frequencies for
categorical data and means or medians for continuous data were presented.

3.6.2 Kappa statistic (κ)
In this study, agreement was estimated by comparing kappa statistic calculated for
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prescription medication use for chronic (represented by diabetes medication use) and
acute (represented by opioid analgesics) conditions. Kappa statistic is a common measure
of validity and reliability of categorical data which takes into account the agreement that
can occur due to chance. It can have values from -1 to 1. Several classifications have
been proposed for interpreting kappa values and this study would utilize the classification
proposed by Landis and Koch [94]. According to this classification, if kappa value lies
between 1.0 and 0.8 then it is regarded as almost perfect agreement [94]. If the kappa
value lies between 0.8 and 0.6 then it is considered a substantial agreement, whereas if
the value lies between 0.6 and 0.4 then it is considered to be a moderate agreement.
Kappa value between 0.4 and 0.2 is considered as fair agreement, value between 0.2 and
0 is considered slight, and kappa value below zero is poor agreement [94]. This is shown
below in Table 8.
Table 8: Landis and Koch’s classification for interpretation of a kappa value
Range of kappa value (κ)
Interpretation
1.0 – 0.8

Almost perfect

0.8 – 0.6

Substantial

0.6 – 0.4

Moderate

0.4 – 0.2

Fair

0.2 - 0

Slight

0 - -1

Poor

Usually, for calculation of kappa statistic, a 2 X 2 table is used as shown below in
Figure 1. Cells „a‟ and „d‟ represent the number of cases where there is agreement
between both the gold-standard and the observer for the presence and absence of the
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outcome of interest. Cells „b‟ and „c‟ represent the number of cases where the gold
standard and the observer do not agree on the presence of the outcome. Calculation of
kappa statistic takes into consideration the difference between the agreement actually
present (proportion of observed agreement, Po) and the agreement that is present by
chance alone (proportion of expected agreement, Pe). It is calculated as follows:

Observer
(Self-report)
Yes
No
Total

Gold Standard (Medical Records)
Yes
No
a
c
a+c

b
d
b+d

Total
a+b
c+d
N= a+b+c+d

Figure 1: A 2X2 table for calculation of kappa statistic
Kappa statistic (κ) = observed agreement (Po) – expected agreement (Pe)
1- expected agreement
Where, observed agreement, Po = (a+d) / N
expected agreement, Pe = [(a+c) (a+b) + (b+d) (c+d)] / N2

3.6.3 Prevalence-adjusted and bias-adjusted kappa (PABAK)
Even though kappa statistic is widely used to measure agreement between two
raters, it suffers from certain limitations, most notable of them being its dependence on
prevalence [95, 96]. If the horizontal and vertical marginal cells of a 2 X 2 table are
relatively unbalanced, i.e., the prevalence of the desired outcome is either very low or
high, the value of kappa statistic maybe misleading. For instance, it may signify a low
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level of agreement, even if the proportion of observed agreement is high. Feinstein and
Cicchetti have described this phenomena as the kappa paradox [95]. To correct this, Byrt
et al. proposed the use of prevalence-adjusted and bias-adjusted kappa (PABAK) [96] .
The effect of prevalence can be assessed by calculating the prevalence index (PI). It is
calculated by the following formula:
PI = | a-d |
N

If the prevalence index is high, the expected agreement is also high and the
corresponding kappa value is lower [96, 97]. Bias index (BI) represents the extent to
which propensity of two raters to classify the occurrence of the outcome in yes or no
categories differs [96]. It is calculated as:
BI = | b-c |
N

PABAK adjusts the kappa statistic for the influence of high and low prevalence
by substituting the actual values of cells „a‟ and „d‟, by their average values. Similarly,
for adjusting the bias introduced due to different observers, values for cells „b‟ and „c‟ are
replaced by their average values. The 2X2 contingency table then looks like this:

Gold Standard (Medical Records)
Observer
(Self-report)
Yes
No

Yes

No

p
q

q
p
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Where, p = (a+d) / 2 and,
q= (b+c) / 2
Using these values to calculate PABAK, we get [96]
PABAK = 2Po - 1
An alternate version of this equation, using the prevalence index and bias index values
gives [96],
PABAK = κ (1- PI2 +BI2) + PI2 - BI2
Hoehler has criticized the use of PABAK citing that adjusting for prevalence and bias
effects might result in overestimation of kappa [97]. Our choice to use PABAK was
driven by the inherent limitations in the kappa statistic, which PABAK takes care of.
While there is no consensus as to what measure of agreement should be reported,
researchers have advocated that it is more insightful to present more than one measure of
agreement [97]. In our study, there was a considerable prevalence effect due to no data in
the cell „d‟ (medical record- “No”, self-report- “No”).

3.6.4 Sensitivity and specificity
In addition to measures of agreement, sensitivity and specificity of the maternal
self-report in comparison with information in medical records (the „gold standard‟) were
also calculated as measures of validity. Sensitivity and specificity are common measures
used to assess the indicative ability of any test [98]. While sensitivity is the ability of any
test to correctly identify those who have the outcome of interest, specificity is the ability
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of any test to correctly identify those who do not have the outcome of interest. Sensitivity
is calculated as the number of true positives divided by a combination of the number of
true positives and the number of false positives. Specificity is calculated as the number of
true negatives divided by a combination of the number of true negatives and the number
of false negatives). This is illustrated in the following figure:

Observer
(Self-report)
Yes

Gold Standard (Medical Records)
Yes
No

Total

a b

a+b

TP

FP
c d

No
FN
a+c

Total

c+d
TN
b+d

Where, TP = True positives
FP = False positives
TN = True negatives
FN = False negatives
Sensitivity = TP/ (TP + FN)

= a/ (a+c)

Specificity = TN/ (FP + TN) = d/ (b+d)

Figure 2: Sensitivity and specificity

3.7 Hypothesis testing
Statistical analyses conducted to test the study hypotheses are presented below:
Research hypothesis 1: Agreement between self-reported information and information in

52

the medical records will be greater for medications prescribed for chronic medical
conditions (represented by diabetes medication), compared with prescription medications
given for acute medical conditions (represented by opioid analgesic) in the SMART study
cohort.
Unit of analysis: Major therapeutic class of chronic and acute medication as identified for
this study.
Kappa statistic, prevalence-adjusted and bias-adjusted kappa (PABAK) and
observed proportion of agreement (Po) values were calculated for each class of
antidiabetic and opioid analgesic medications as identified in Table 3 and 4.Value of
kappa statistics and PABAK for each class was then pooled by taking their overall mean
(commutative) kappa value for prescription medication for diabetic medication. This is
illustrated in the formula below:
Mean kappa for diabetic medication use = Sum of kappa values from all classes
Number of drug classes

Similarly, mean kappa was computed for opioid analgesic medication as:
Mean kappa for opioid analgesics = Sum of kappa values from all classes
Number of drug classes

The mean kappa value was used to compare the difference in agreement between
chronic and acute medication use. Sensitivity and specificity of self-reported information
by the patients about prescription medication use were also calculated for antidiabetic and
opioid analgesic drug use by using information from the medical records as the „goldstandard‟.
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Research hypothesis 2: To examine the predictors of inaccurate reporting in this UNMbased study cohort.
Unit of analysis: Study subjects with inaccurate information about prescription
medication use.
A multivariate logistic regression analysis was performed to identify the
significant predictors of inaccurate reporting in this study. The outcome of interest for
this analysis was inaccurate report of prescription medication use. For this, inaccurate
reporters for each medication class were first identified. These inaccurate reporters
consisted of those patients who had discordant information regarding prescription
medication use (Table 6).
Therefore, according to the example in Table 7, pat#002 is an inaccurate reporter
for insulin use, and pat#003 is an inaccurate reporter for sulfonylurea use. Thus in other
words, a patient was considered to be an inaccurate reporter if the information about
medication use was present in the medical records but not in the self-report, or vice versa.
In the case multiple medication use, patients were classified as inaccurate
reporters if they inaccurately reported medication use for even one class of medication,
even if they had concordant information for the rest of the classes of medication. This
method has previously been used in studies assessing recall of medical conditions, where
the researchers employed the above mentioned method to identify inaccurate reporters for
reporting diagnosis of chronic conditions [15, 48, 60, 65]. To identify inaccurate reporters
among multiple medication users, an alternative method of classification for
accurate/inaccurate reporting of medication use would have been to have multiple
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observations per person, i.e., one observation for each medication use (for e.g., if a
patient is on five different classes of medications, that patient would be present in the
database five times, once for each class), and then assess the accuracy of recall. However,
in this method the observations would no longer be independent and it would violate the
assumption of the logistic regression analysis of independent observations. This would
have resulted in erroneous results. Therefore, inaccurate reporters were classified
according to the method used in previous studies. This method does not violate the
assumptions of logistic regression and the observations are independent of each other.
Dependent variable was dichotomous (inaccurate report; yes=1/no=0).
Since no prior studies have been conducted among pregnant to assess the
predictors of inaccurate recall regarding medication use, demographic factors were
chosen based on prior studies done in the general population. Medical/reproductive
factors were included based on prior studies conducted among pregnant women that
assessed predictors of medication use. Health literacy is defined as the ability of patients
to read, understand and act on medical instructions. Level of health literacy of a patient
can influence the extent of agreement for medication use. Knowledge and attitude factors,
along with educational status reflect the extent of health literacy among the study
participants and were used as proxy measures of health literacy.
Inaccurate reporters from all the medication classes were then pooled together and
constituted the study sample for the analyses for this study hypothesis. The following
representation shows how this looked like in the database.
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Pat id
001
002
003

Inaccurate reporter
0
1
1

Univariate analyses using the Chi-square/ Fisher‟s exact test and t-test methods
(as appropriate) were performed to identify any significant difference between the groups
(inaccurate reporters and accurate reporters). Potential predictors were tested for
significance at p<0.20 in univariate analyses [99]. Thereafter, multivariate regression
analysis was conducted to estimate if the selected covariates predict inaccurate reporting
for prescription medication use. Covariates included in the final multiple regression
model included: insurance status (no insurance as reference category), place of birth
(place of birth outside United States as reference category), at least one episode of binge
drinking (≥ 4 drinks/occasion) around LMP (no episode of binge drinking as reference
category), presence of chronic conditions (no chronic conditions as reference category),
and gestational age at the time of interview (gestational age ≤ 20 weeks as reference
category), and number of unique prescription medications.
Significance was tested at p<0.05. All the analyses for hypotheses testing were
conducted by using SAS software (version 9.1.3).
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CHAPTER 4 - RESULTS

This chapter presents the results of the study. A description of the study
population is presented, followed by the results for the measures of agreement. Finally,
the results of the multiple logistic regression analysis with respect to important predictors
of inaccurate report are presented.
4.1 Description of the study sample:
Results from the descriptive analyses are presented in Tables 9-11.

4.1.1 Demographics and lifestyle characteristics
Demographic and lifestyle information is presented in Table 9. The mean age of
the study participants was 29.2 ± 6.1 years and half of the patients (50%) were more than
30 years old. More than three-fourths of the participants had a high school or higher
degree (77.2%), with about 31.5% reporting having a vocational or college degree. In
contrast, about 22.8% indicated that they had educational experience of less than high
school. About 40.2% of the participants were either married or living with a partner and
almost an equal proportion (39.1%) of them were separated, divorced or widowed. About
a third (33.7%) of the study participants did not have any insurance coverage.
More than half (54.3%) of the study participants spoke English as their primary
language, whereas 43.5% indicated Spanish was their primary language. A majority
(59.8%) of the participants were born in the United States and were of Hispanic ethnicity
(67.4%).
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About 65.2% of the study participants reported that they had never smoked
cigarettes or used tobacco. About a third of the women (32.6%) indicated that they were
past smokers (quit smoking upon recognition of pregnancy or before that). Only two
women (2.1%) reported at the time of the interview that they were still active smokers
(current smokers). Almost a third of the women (29.4%) reported that they had engaged
in „binge drinking‟ (consumption of 4 or more drinks at a single occasion), at least once
in the periconceptional period.

4.1.2 Knowledge and attitude towards medication use during pregnancy
Table 10 shows the results about knowledge and attitude factors regarding
medication use during pregnancy in this study cohort. Majority of the participants
(86.9%) had sought consultation about the safety of medications they took during
pregnancy. Majority of the participants (70.3%) reported that upon recognition of
pregnancy, consumption of „only necessary‟ medications should be continued, while
about a quarter (26.4%) of them indicated that all the medication should be stopped upon
recognition of pregnancy. Among study participants, majority had accurate knowledge
about how often medication use can during pregnancy cause birth defects („sometimes‟:
70.4%), while about a quarter (28.3%) of the participants had exaggerated perception of
teratogenicity and indicated that medications used during pregnancy can cause birth
defects „often‟, „very often‟ or „always‟. A majority of the women (94.6%) in the study
sample also indicated that consumption of alcohol should be stopped upon recognition of
pregnancy.
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Table 9: Demographic and lifestyle characteristics of the study population (N=92)
Variable
N (%)*
DEMOGRAPHIC FACTORS
Age
18-23 years
24-29 years
30 years and above
Educational level
Less than high school
High school/GED
Some College/Vocational school
College degree
Masters, doctorate or professional degree
Marital status
Single, never married
Married/Living with partner
Separated/Divorced/Widowed
Insurance status
No insurance
Have any insurance
Ethnicity
White, non-Hispanic
White, Hispanic
Other
Place of birth
United States
Outside United States
Primary language
English
Spanish
Other
LIFESTYLE FACTORS
Smoking status
Never smoked
Current smoker
Past smoker
Quit before pregnancy recognition
Quit after pregnancy recognition
At least one episode of binge drinking ( ≥ 4 drinks
/occasion) around last menstrual period (LMP)
Yes
No
* Sample size might vary due to missing data
** Decimal points have been rounded off
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21 (22.8)
25 (27.2)
46 (50.0)
21 (22.8)
32 (34.8)
29 (31.5)
07 (7.6)
03 (3.3)
19 (20.7)
37 (40.2)
36 (39.1)
31 (33.7)
61 (66.3)
15 (16.3)
62 (67.4)
15 (16.3)
55 (59.8)
37 (40.2)
50 (54.3)
40 (43.5)
02 (2.1)

60 (65.2)
02 (2.2)
30 (32.6)
19 (20.6)
11(12.0)

27 (29.4)
65 (70.7)

Table 10: Knowledge and attitude about medication use and alcohol consumption
during pregnancy (n=92)
Variable
N (%)*
Attitude towards medication use during pregnancy
Stop taking all the medications upon recognition of pregnancy
Continue with necessary medications
Continue taking all the medications as needed
How often can medications cause birth defects
Never
Sometimes
Often
Very often
Always
Attitude towards alcohol consumption during pregnancy
Should abstain
OK to consume some alcohol
OK to drink wine/beer, but not hard drinks
Sought consultation about safety of medication
Yes
No
* Sample size might vary due to missing data
** Decimal points have been rounded off.

24 (26.4)
64 (70.3)
03 (3.3)
01 (1.2)
57 (70.4)
12 (14.8)
04 (4.9)
07 (8.6)
87 (94.6)
04 (5.4)
0
80 (86.9)
12 (13.0)

4.1.3 Medical and reproductive history
The results of medical and reproductive history are presented in Table 11. Nearly
three-fourths of the women (73.9%) reported at least one chronic condition at the time of
interview. More than half (54.3%) of the women reported a diagnosis of preexisting or
gestational diabetes. This can be explained by the sampling procedure utilized for the
study, i.e., selection of participants having a prescription for either antidiabetic or opioid
analgesic medication which contributed towards a high prevalence of chronic conditions,
especially diabetes, in this cohort. Other most commonly reported chronic conditions
reported in this study sample were migraine headaches (17.4%), asthma/allergies (10.9%)
and depression (9.8%).
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The mean gestational age of the study participants at recruitment was 32.5 ± 5.9
weeks, with 93.5% of subjects recruited after 20 weeks gestation. A third (29.7%) of the
study participants had a history of adverse perinatal outcomes. Prior adverse perinatal
outcomes included: miscarriage (32.6%), stillbirth (1.08%), termination (9.78%) and,
ectopic pregnancy (2.17%). About 71.4% of participants reported that they had given
birth to a live child before (multiparous), while for 17.6% of women, this was the first
time they were pregnant (primigravida).

Table 11: Medical and reproductive history of the study sample (n=92)
Variable
Mean± S.D.
Gestational age at the time of interview (weeks)
Variable
Presence of chronic conditions
None
At least one
History of adverse perinatal outcomes
Yes
No
Gravidity
Primigravid
Multigravid
Parity
Nulliparous
Parity more than one
Gestational age at the time of interview
Less than or equal to 20 weeks
More than 20 weeks

32.5 ± 5.9
N (%)*

24 (26.1)
68 (73.9)
27 (29.7)
64 (70.3)
16 (17.6)
75 (82.4)
26 (28.6)
65 (71.4)
06 (6.5)
86 (93.5)

* Sample size might vary due to missing data
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4.2 Measures of agreement and validity
4.2.1 Prevalence of major therapeutic classes use
Prevalence of medication use was estimated for both data sources used, i.e., selfreport from the SMART study questionnaire and the medication use data abstracted from
the patients‟ electronic medical records (EMRs). No recorded use was found for „mixed
agonist-antagonist/partial agonist class‟ and „other opioid analgesic class‟ for opioid
analgesics, therefore they were not included in any analyses to assess the measures of
agreement. Average duration of opioid analgesic use among study participants was 5.3
days. None of the study participants were found to be chronic users of opioid analgesics
as per the definition of chronic users for the purposes of this study. Thiazolidinedione
(TZD) class for antidiabetic medication had only one recorded use from the medical
records; therefore it was also excluded from the main analyses for estimating the measure
of agreement. The results are presented in Table 12.
Among antidiabetic medication use, sulfonylurea had the highest recorded use
(29.4%), followed by insulin and its analogues (23.9%) and biguanides (22.8%). For
opioid analgesic use, the highest recorded use was found for strong agonists (42.4%),
followed by moderate/low agonist use (22.8%).
Among antidiabetic medication, almost equal proportion of use was found for
insulin (21.7%; for both self-report and medical record) and biguanides (21.7% use
documented in self-report vs. 20.7% documented use in the medical records). For
sulfonylureas, considerable difference in the documented use in the two data sources was
found (22.8% use in self-report vs. 29.7% use documented in the medical records).
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Similar results were obtained for use of strong agonist class of opioid analgesics, i.e., data
from the medical records indicate that about 39.1% of the sample were prescribed strong
opioid analgesics, while only 23.9% reported its use by self-report.

Table 12: Prevalence of Medication Use by Reporting Source (N=92)
Drug class
Self-report
Medical record
Total
N (%)
N (%)
prevalence
N (%)
ANTIDIABETIC MEDICATION
Insulin and its analogues
20 (21.7)
20 (21.7)
Sulfonylureas
21 (22.8)
27 (29.4)
Biguanides
20 (21.7)
19 (20.7)
Thiazolidinediones (TZDs)
0
1 (1.1)
OPIOID ANALGESIC MEDICATION

22 (23.9)
27 (29.4)
21 (22.8)
01 (1.1)

Strong agonists
Moderate/Low agonists
Mixed agonist-antagonists
and partial agonists
Other

22 (23.9)
10 (10.9)
0

36 (39.1)
13 (14.1)
0

39 (42.4)
21 (22.8)
0

0

0

0

4.2.2 Measures of agreement/concordance
For measures of agreement, simple kappa and 95% confidence interval,
prevalence-adjusted-bias-adjusted kappa (PABAK), and proportion of observed
agreement (Po) were estimated. Information regarding medication use from the medical
records was used as the gold-standard. Agreement between self-report and medical
records varied by drug class, as shown in Table 13. Overall, almost perfect agreement
was found for antidiabetic medication use (mean kappa=0.87 and mean PABAK=0.91) in
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contrast to poor-to-moderate agreement for opioid analgesics (mean kappa=0.29 and
mean PABAK=0.57).
Among antidiabetic medications, agreement was highest for biguanide use
(κ=0.90, CI=0.79; 1.00, PABAK=0.9, Po=0.97), followed by insulin use (κ=0.87,
CI=0.75; 0.99, PABAK=0.93, Po=0.95) and sulfonylurea use (κ=0.83, CI=0.70; 0.96,
PABAK=0.87, Po=0.93). For opioid analgesic use, while PABAK and proportion of
observed agreement (Po) were similar for the two classes included in the analysis (strong
agonist: PABAK=0.65, Po=0.78; moderate/low agonist: PABAK score=0.59, Po=0.79),
simple kappa varied significantly (κ for strong agonists=0.51, 95% CI=0.33; 0.69, κ for
moderate/low agonists=0.06, 95% CI= - 0.17; 0.29).

Table 13: Measures of concordance/agreement* (N=92)
Drug Class
Simple kappa
p-value PABAK**ǂ
(95% CI)

Proportion of
observed
agreement
(PO)

ANTIDIABETIC MEDICATION
Insulin and its
analogues
Sulfonylureas
Biguanides

Strong agonists
Moderate/Low agonists

0.87 (0.75;0.99)

0.93

0.95

0.83 (0.70;0.96)
<0.001
0.87
0.90 (0.79;1.00)
<0.001
0.93
OPIOID ANALGESIC MEDICATION

0.93
0.97

0.51 (0.33;0.69)
0.06 (-0.17;0.29)

<0.001

<0.001
0.29

0.56
0.59

0.78 (78.2%)
0.79 (79.3%)

* Medical record information is the “gold-standard”.
ǂ 95% CI for PABAK not calculated.
*** „Thiazolidinedione‟, „Mixed agonist-antagonists /partial agonists‟ and, „other opioid‟ classes were
excluded from analyses because of empty cells i.e., no reported use either in self-report or medical records.
**** Decimal points have been rounded off.
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Table 14: Sensitivity and specificity measures using medical records as the ‘goldDrug class
Sensitivity (%) (95% CI) Specificity (%) (95% CI)
ANTIDIABETIC MEDICATION *
Insulin
Sulfonylurea
Biguanides

0.90 (0.68-0.98)
0.97 (0.90-0.99)
1.00 (0.83-1.00)
0.92 (0.82-0.97)
0.90(0.68-0.98)
0.99 (0.93-0.99)
OPIOID ANALGESIC MEDICATION **

Strong opioid agonist
Moderate opioid agonist

0.86 (0.65-0.97)
0.20 (0.02-0.55)

0.76 (0.64-0.85)
0.87 (0.77-0.93)

* Sensitivity and specificity not calculated for Thiazolidinedione‟ because of small sample size.
** Sensitivity and specificity not calculated for „Mixed agonist-antagonists /partial agonists‟ and, „Other
opioid‟ because of empty cells i.e., no reported use either in self-report or medical records.
*** Decimal points have been rounded off.

4.2.3 Sensitivity and specificity measures
Sensitivity and specificity scores with 95% confidence interval were estimated.
The results are shown in Table 14. Overall, good sensitivity and specificity measures
were obtained for antidiabetic medication use. While sensitivity and specificity were
similar for insulin and biguanides use, sulfonylurea use had higher sensitivity but lower
specificity. For opioid analgesic medication use, 86.3% sensitivity was obtained while
specificity was 75.7%. Use of moderate opioid agonists was associated with a very low
sensitivity of 20%, whereas specificity was 86.5%.
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4.3 Predictors of inaccurate reporting of prescription medication use
Significant covariates identified in the univariate analysis included: maternal age ,
insurance status, place of birth, at least one episode of binge drinking since LMP,
presence of chronic conditions, gestational age at the time of interview, and the number
of unique prescription medications per patient (prescription burden). After controlling for
all the other covariates in the model, episode of binge drinking and presence of chronic
conditions was found to be significantly associated with inaccurate reporting of
prescription medication use. Specifically, women who reported at least one episode of
binge drinking since their LMP were 3.4 times more likely (95% CI: 1.13; 10.29) to
inaccurately report prescription medication use during pregnancy.

Table 15: Results of univariate tests (N=92)
Variable
Accurate
reporters
(N=45)
N (%)
Age
18-23 years
08 (17.8)
24-29 years
12 (26.7)
30 years and above
25 (55.6)
Educational level
Less than high school
11 (24.4)
High school/GED
16 (35.6)
College and above
18 (40.0)
Marital status
Single, never married
08 (17.8)
Married/Living with partner
20 (44.4)
Separated/Divorced/Widowed
17 (37.8)
Insurance status
No insurance
18 (40.0)
Have any insurance
27 (60.0)
Ethnicity
White, non-Hispanic
06 (13.3)
White, Hispanic
31 (68.9)
66

Inaccurate
reporters
(N=47)
N (%)

p-value

<0.0001*
13 (27.7)
13 (27.7)
21 (44.7)
0.97
10 (21.3)
16 (34.0)
21 (44.7)
0.31
11 (23.4)
17 (36.2)
19 (40.4)
0.02*
13 (27.7)
34 (72.3)
0.57
09 (19.1)
31 (66.0)

Variable

Other
Place of birth
United States
Outside United States
Primary language
English
Spanish
Other
Smoking status
Never smoked
Past smoker
Current smoker
At least one episode of binge drinking
( ≥ 4 drinks /occasion) around LMP
Yes
No
Attitude towards medication use
during pregnancy
Stop taking all the medications upon
recognition of pregnancy
Continue with necessary medications
Continue taking all the medications as
needed
How often can medications cause birth
defects
Never
Sometimes
Often
Very often
Always
Attitude towards alcohol consumption
during pregnancy
Should abstain
OK to consume some alcohol
Sought consultation about safety of
medication
Yes
No
Presence of chronic conditions
None
At least one
History of adverse perinatal outcomes
Yes

Accurate
reporters
(N=45)
N (%)
08 (17.8)

Inaccurate
reporters
(N=47)
N (%)
07 (15.0)

22 (48.9)
23 (51.1)

33 (70.2)
14 (29.8)

p-value

0.005*

0.28
20 (44.4)
25 (55.6)
0

30 (63.8)
15 (31.9)
02 (4.3)

32 (71.1)
13 (28.9)
0

28 (59.6)
17 (36.2)
02 (4.3)

0.49

0.005*
07 (15.6)
38 (84.4)

20 (42.6)
27 (57.4)
0.32

12 (26.7)

12 (25.5)

29 (64.4)
03 (6.7)

35 (74.5)
0
0.28

01 (2.2)
31 (68.9)
04 (8.9)
03 (6.7)
02 (4.4)

0
26 (55.3)
08 (17.0)
01 (2.1)
05 (10.6)
0.62

43 (95.6)
02 (4.4)

44 (93.6)
02 (4.3)
1.00

39 (86.7)
06 (13.3)

41 (87.2)
06 (12.8)
0.03*

07 (15.6)
30 (66.7)

17 (36.2)
38 (80.9)

13 (28.9)

14 (29.8)

1.00
67

Variable

No
Gravidity
Primigravid
Multigravid
Parity
Nulliparous
Parity more than one
Gestational age
Less than or equal to 20 weeks
More than 20 weeks
Number of unique prescription
medications (prescription burden)
*= significant at α= 0.2.
** Decimal points have been rounded off.

Accurate
reporters
(N=45)
N (%)
32 (71.1)

Inaccurate
reporters
(N=47)
N (%)
32 (68.1)

07 (15.6)
38 (84.4)

09 (19.1)
37 (78.7)

p-value

0.95

0.86
13 (28.9)
32 (71.1)

13 (27.7)
33 (70.2)

02 (4.4)
43 (95.6)
Mean (SD)
4.7 (3.5)

03 (6.4)
44 (93.6)
Mean (SD)
6.1 (5.4)

<0.0001*
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<0.0001*

Table 16: Predictors of inaccurate reporting of prescription medication use
Maternal characteristic/predictor
Adjusted Odds
95% CI
p-value
ratio
Age
18-23 years
24-29 years
30 years and above
Insurance status
No insurance
Have any insurance
Place of birth
United States
Outside United States
At least one episode of binge drinking ( ≥ 4
drinks /occasion) around LMP
Yes
No
Presence of chronic conditions
None
At least one
Gestational age
Less than or equal to 20 weeks
More than 20 weeks
Number of unique prescription
medications (prescription burden)
Note:
1.
2.
3.
4.
5.

0.75
1.0*
1.32
1.76

-0.33; 5.28
0.45; 6.98
0.27

3.5
1.0*

0.32; 37.03
--

5.80
1.0*

0.57; 58.79
--

0.13

0.03**
3.40
1.0*

1.13; 10.29
-0.07

1.0*
0.28

-0.08; 1.00

1.0*
1.83
1.03

-0.29; 11.42
0.94; 1.138

0.52

0.49

* = Reference category
** = significant at α = 0.05
All odds ratio are adjusted for all variables in the table.
Non significant covariates as identified in the bivariate analysis were not included in the final
model.
Decimal points have been rounded off.
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CHAPTER 5 DISCUSSION
This chapter presents a discussion about the descriptive results of the study
followed by discussion on the results of the main analyses. Limitations of the study are
then discussed, followed by implications and recommendations for future research.
5.1 Discussion of descriptive findings
The study was conducted in a predominantly Hispanic population (67.4%). This is
particularly noteworthy because none of the earlier studies to assess agreement for
prescription medication use among pregnant women have been conducted in a primarily
Hispanic population. The sample was recruited from UNM Main Hospital and five
community clinics that are situated throughout the city of Albuquerque, New Mexico,
which allowed for capturing a socio-economically diverse sample and reduce selection
bias. The interview for obtaining self-reported information about prescription medication
use was conducted both in English and Spanish, therefore omitting the potential
confounding due to language.
One finding worth noting in this study sample was that majority of the women
had educational experience of high school and above (77.2%), of which 7.6% had a
college degree. While high educational status has been reported as a predictor of higher
recall for prescription medication use, this was not the case in this study sample. About
three-fourths of the sample (66.3%) had some kind of insurance coverage. Lack of
insurance coverage has been reported as predictor of low agreement for prescription
medication use. In our study, however, we were unable to find a significant association
between the two.
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Women in this study sample, in general had more accurate knowledge regarding
alcohol consumption and medication use during pregnancy. About 70 % women reported
that upon recognition of pregnancy, only necessary medication should be taken after
consultation with a medical practitioner. This is in accordance with the current guidelines
on prescription medication use during pregnancy [2, 9, 25]. About 87% of the women in
the sample had sought consultation about the medication they were taking during
pregnancy. This can be explained in part, by our sample selection. Since, we were
interested in assessing accuracy of prescription medication use; women in our sample had
some type of prescription medication, and must have sought consultation about the
medications that were prescribed to them. Majority of the women (94.6%) reported that
alcohol consumption should be stopped during pregnancy. This is also in line with the
guidelines by U.S. Surgeon General‟s advisory on alcohol use during pregnancy [100].

5.2 Measures of agreement
The primary objective of this study was to assess whether agreement for
prescription medication use is influenced by the type of medication use (chronic vs.
acute). The findings of the study indicate that agreement for antidiabetic medications, i.e.,
chronic use, was much higher as compared to that for opioid analgesics, i.e., acute use.
While almost perfect agreement was obtained for all the classes of antidiabetic
medications, poor-to-moderate agreement was obtained for opioid analgesic use.
Even though previous research has shown that accuracy of recall for prescription
medication use differs according to the therapeutic category under investigation [29, 50,
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68, 70], various studies conducted in the general population have consistently reported a
higher level of agreement for prescription medications used for a longer duration or
„chronically‟ [26, 29, 68, 75, 76]. Consistent with the findings of these studies, we
obtained high agreement for prescription medications used chronically to control diabetes
(κ = 0.87; PABAK = 0.91). Agreement for specific drug classes of antidiabetic
medications has also been previously reported in the literature among non-pregnant
women. Moderate-to-substantial agreement for insulin and its analogues (κ =0.6 to κ
=0.78) [26, 70] and oral hypoglycemics (κ =0.75) [70] has been reported. Specifically, κ
=0.60 has been reported for biguanides and TZDs [26], whereas for sulfonylureas
moderate-to-excellent agreement has been reported (κ =0.60 [26] and κ =0.93 [39]. Our
study demonstrates even higher agreement for these specific drug classes (insulin: κ
=0.87, PABAK=0.93; sulfonylurea: κ =0.83, PABAK=0.87; biguanides: κ =0.90,
PABAK=0.93). Our kappa value for sulfonylurea medications was however lower than
the one obtained by Glintborg et al [39].
For self-reported opioid analgesic medication use among non-pregnant
populations, low-to-moderate agreement has been reported in the literature in the range of
κ =0.15-0.49 [26, 68, 70]. In accord with these previously reported values, we also found
low agreement for opioid analgesic use in our sample (κ =0.29; PABAK=0.57).
Agreements for specific classes of opioid analgesics have not been reported in the
literature; therefore we were unable to make any comparisons.
Among pregnant women, only a few studies have reported agreement for
prescription medication use [30, 40, 85, 88]. These earlier studies have used different
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methodologies to ascertain agreement for prescription medication use. Bryant et al. used
medical records as the „gold-standard‟ to assess accuracy of self-report of prescription
medications used in a cohort of pregnant women [30]. While their choice of „goldstandard‟ was similar to ours, their method of ascertaining information about prescription
medication use was different in that they asked for report of „any‟ prescription
medication use. The results of this study therefore, only reveal information on the
agreement of use of prescription medication among pregnant women.
In another study conducted by de Jong et al., the researchers assessed the
agreement by estimating sensitivity and specificity measures for specific therapeutic
categories (including antibiotics, antacids, anesthetics, hypnotics/sedatives, tocolytics,
and oxytocics), that did not include our therapeutic categories of interest (i.e.,
antidiabetics and opioid analgesics) [88]. In addition, their data sources and „goldstandards‟ were also different from what we have utilized in our study. They used
information on medication use collected at the time of prenatal visits by pregnant women,
and compared it with data collected seven years later [88]. Their choice of „goldstandard‟ has a serious flaw, as recall diminishes with increase in the recall interval [16,
28, 70, 71]. This might have caused considerable recall bias in the study.
However, the study conducted by Olesen et al. improved upon these
methodological flaws by utilizing prescription database as the „gold-standard‟, which
provided with the information about the medications that were actually dispensed [40].
Even though this information does not suggest that the patient actually consumed the
medication, it at least provides with an indicator that the medications were dispensed and
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may have been used by the patient. Olesen et al. assessed agreement for the most
commonly used prescription medications in their cohort [40]. This was the only study
that assessed agreement for specific classes of medication. They found perfect agreement
(100%) for insulin use [40]. This was the only medication class that we could compare to
in previous reports. These results are also in accordance with our posited hypothesis that
medications used for longer duration (i.e., antidiabetic medications) are recalled
accurately.
However, our results are more robust than Olesen et al, as we calculated kappa
statistic that takes into account agreement that can occur due to chance, while Olesen et al
estimated agreement percent agreement. Further, we also estimated PABAK that adjusts
for dependence of the kappa statistic on prevalence of the outcome if interest.

5.3 Predictors of inaccurate reporting
Our results indicate that women who had at least one episode of binge drinking
were more likely to inaccurately report the use of prescription medications, independent
of other factors like age, insurance status, place of birth, presence of chronic conditions
gestational age, and number of unique prescription medications. About 30% of our study
participants reported at least one binge drinking episode (≥ 4 drinks per occasion) before
pregnancy recognition a month around LMP. This finding holds a great significance
given that heavy drinking during pregnancy can result in fetal alcohol spectrum disorder
(FASD). Alcohol consumption during pregnancy itself is considered a risky behavior. If
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binge drinking further leads to inaccurate reporting of prescription medication use, then it
calls for increased surveillance over such women regarding the information they provide
for prescription medication use. Previous research indicates that high alcohol intake is
associated with lower agreement regarding prescription medication use among women
[101]. Merlo et al in their study conducted in a cohort of Swedish women found that
women who engaged in high alcohol consumption were 1.47 times more likely (95% CI;
1.09:1.97) to inaccurately report their prescription medication use, as compared with
women who did not engage in high alcohol consumption. While this study could not
demonstrate that alcohol consumption can lead to inaccurate reporting of prescription
medication use as the women included in this study were slightly older (45-73 years), it
does demonstrates that alcohol intake can influence agreement regarding medication use
among women in general.
Since during medication reconciliation, it is not possible to ascertain that the
recorded medications are actually consumed, medical records of women engaging in
alcohol consumption or binge drinking, especially the information that they provide
regarding their prescription medication use should be supplemented with other sources of
information, e.g., pharmacy records.
Age, educational status, insurance status, and number of medications used are the
other most commonly reported predictors for accuracy of recall for prescription
medication use [29, 71, 75, 102]. In this study, however we were unable to obtain
significant association with these commonly reported predictors with respect to accuracy
of recall of prescription medication use.
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5.4 Limitations
The findings of this study should be interpreted in light of a few limitations
associated with the study design. These limitations are presented below:
1. There might have been variability in patient recall based on the interval between
the timing of the interview and the timing of prescription medication use. The
mean gestational age at enrollment was 32.5 weeks ± 6.0. Most of the women in
the study sample were interviewed in the late second or early third trimesters.
Recall interval has been reported to be a significant predictor of agreement for
prescription medication use in the general population [28]. Olesen et al. and
Bryant et al. have also reported that the recall interval can influence recall among
pregnant women [30, 40]. However, in this study we did not assess the association
between the recall interval and accuracy of report.
2. Recall can also be influenced by the route of medication used by the patient, as
the patient is more likely to remember those medications for which they have to
follow specific instructions, over those that do not have any such instructions for
administration, such as, parenteral vs. oral medications. This has been previously
reported in the literature as one of the factors [68, 73].
3. Due to the small sample size (92 patients), power of the study was limited and did
not allow for comparisons by specific medications. Therefore, for the purposes of
this study, agreement was ascertained by the major class of medications instead of
specific medications. Comparison by specific drugs would have been more
accurate but was not logistically feasible due to the small sample size.
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4. In this study, we were assessing validity for the most common chronic and acute
medication use that are used during pregnancy. Therefore, the results of this study
cannot be generalized to classes of medications other than those utilized in this
study.
5. The study results have limited generalizability since it was conducted at one
location only (UNMH, Albuquerque); thus, the study sample might not be
representative of the entire U.S. population.
6. Use of electronic medical records
i. In this study, medical records were used as the „gold-standard‟ for assessing
accuracy of self-reported information about prescription medication use.
Researchers argue that no source of information has complete and accurate
information regarding medication use [65, 103]. While self-reported
information is often affected by various information biases, medical records
have also been criticized for not being a complete source of information for
medication use [26, 36, 44]. However, they play an important role in clinical
decision making process [48]. Nowadays, with the increasing use of electronic
medical record (EMR) system, most of the challenges and limitations earlier
associated with medical records, e.g., delayed and erratic recording, illegible
handwriting of physicians, non-documentation of medications taken from an
outside provider, and very limited information about lifestyle and behavioral
characteristics, are taken care of [104, 105]. Apart from streamlining and
improving the documentation of patient related data, data in EMRs can also be
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used in clinical research, and safety and quality assurance studies [104, 105].
UNM Hospital has been using the PowerChart® system by Cerner Corporation
for managing the medical information and prescription medication lists. In this
study, therefore, medical records were used as the „gold-standard‟ as they were
the most comprehensive and updated source of information regarding the
medication use.
ii. One limitation associated with this study was absence of information about
prescription medications prescribed by a provider other than those at UNMH.
In PowerChart, only information about medication prescribed by a UNMH
provider is present. It is possible that patients enrolled in the study could have
seen other providers outside of UNMH. Information about prescription
medications prescribed by those outside providers was not present in
PowerChart, and was available only through patient self-report. 43 patients
(47%) were found to be taking prescription medication from an outside
provider. Further, recent immigrants among this study sample might have
brought prescription medication from other countries. This can influence the
false-positive rate (i.e., patients who do not have a documentation of
prescription medications in the medical records, but reported the use of
medication in self-report). An increase in the number of false-positives can
reduce the specificity of the study. In addition, it is probable that in the
medication reconciliation process, information regarding some prescription
medications might not have been taken out from the medication profiles of the
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patient even if they were discontinued by the patient. This could influence the
false-negative rate (i.e., information about medications present in medical
records, but not reported by the patients). An increase in the number of falsenegatives can reduce the sensitivity of the study. Both of these cases can result
in a decrease in the level of agreement. However, it was not found to be the
case in this study. As can be seen in Table 12, the proportion of self-reported
medication users medication users identified from medical records was similar.
Further, this was also corroborated from the results of sensitivity and specificity
analysis (Table 14), which shows almost perfect sensitivity and specificity for
these two measures.
iii. Finally, for the purposes of this study only the information regarding
documentation of prescription of antidiabetic and opioid analgesics was
abstracted from the electronic medical records (PowerChart®) of the patients.
This documentation of medication is done by the physician attending to the
patient. This information is not suggestive of information on compliance to
those medications by the patients. In the self-report, the patients only report if
they have taken prescription medications that they were prescribed by their
doctor since their last menstrual period. We did not capture adherence, i.e.,
checked if the medications were taken as prescribed. As obtaining this
information is not possible from the PowerChart®, this information might go
uncaptured. This might influence the agreement of medication use, as those
patients who report having received a prescription of a certain medication
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might not have actually used that medication.

5.5 Implications for future research
Future studies should be designed to address the limitations mentioned earlier.
Further studies are needed to explore agreement for other commonly used classes of
medications. As suggested by the findings of this study, patient self-report cannot be
relied upon for medications used for short-term or intermittently. Thus, additional sources
should be used to validate the self-reported information, e.g., pharmacy databases.
Prescription databases and pharmacy claims are reported to be more accurate sources to
validate information about prescription medication use as compared to medical records
[50, 73, 106], since they provide accurate information whether or not a prescribed
medication was filled, but information about the actual exposure is still lacking. If the
sample size permits, analyses should also be done for recall accuracy of specific
medications rather than classes.
Results of this study also provide with some insight on the patient characteristics
associated with inaccurate report of prescription medication use. Results of this study
suggest that information regarding prescription medication use provide by pregnant
women without any chronic conditions and engaging in atleast one episode of binge
drinking may be unreliable. Using these information physicians can develop effective
methods of identifying pregnant women who have these characteristics and are more
likely to inaccurately report their prescription medication use.
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5.6 Recommendations
The reliability of the self-reported information on medication use has importance
in the clinical practice and research where accurate information regarding drug
use/exposure is required. Self-report is the most common method of obtaining
information about medication use. Relying on patient self-report alone can lead to
incorrect estimation of medication exposure, especially for medications taken for shortterm.
With respect to research in the field of safety of medication in pregnancy, often
self-report is the only method of obtaining information regarding drug exposure. Lower
agreement for medications used short-term suggests that self-report for such medication
is unreliable and can lead to misclassification of exposure to medications and erroneous
assessment of teratogenicity. Therefore, other sources like prescription databases to
validate the self-reported medication use are needed. Use of such data sources would also
help in capturing non-compliance, especially in women who are more likely to
inaccurately report their medication use.
Another key area that requires attention is specificity of the questions about
medication use. Previous research demonstrated that agreement depends on the nature of
question asked. If women are asked about the use of a particular medication or given a
list of specific medications, they are more likely to accurately recall medication use as
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compared to situations when they are presented with open-ended questions about
medication use.
In this study, women responded to an open-ended question about prescription
medication use, since they were recruited from multiple specialty clinics and a potential
list of medications would be too long. Recall of medication use could have been better,
especially for opioid analgesic medications, if the question was more specific and
specific brand of generic names of medications were provided.

5.7 Conclusion
The findings of this study suggest poor accuracy of self-report with respect to
prescription medications used as short courses or intermittently during pregnancy.
Accuracy of report for prescription medications taken chronically was higher. Pregnant
who engaged in binge drinking were more likely to inaccurately report use of
medications. Therefore, in clinical studies assessing safety of such medications in
pregnancy, self-reported information needs to be supplemented by other sources.
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APPENDIX 1: DESCRIPTION OF STUDIES IN A TABULAR FORM
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Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Comments

STUDIES CONDUCTED IN GENERAL POPULATION
Haapanen et
al. (1997)
[13]

Middle aged
and elderly
cohort (n=596)

Medical
records

Bush et al.
(1989) [14]

Elderly cohort
(n=120)

Medical
records

Kriegsman et
al. (1996)
[12]

Elderly cohort
(n=2,380)

Information
from
general
practitioners
(“Alloyed
goldstandard”)

Hypertension,
myocardial infarction,
angina pectoris,
coronary heart disease,
claudication, cerebral
stroke, diabetes,
hip/knee arthrosis,
lower back disorder

Had predefined
classification criteria for
identification of medical
conditions in the patients‟
medical record for which
agreement was to be
assessed. Results showed
higher agreement for
chronic conditions and those
conditions that have well
defined diagnostic criteria.
Angina, cancer (any),
Good agreement was
No assumed gold-standard.
cataracts, diabetes,
observed for most
The study reported an
fractures, hypertension, conditions. Highest
overall high percentage
myocardial infarction,
agreement were noted for
agreement, which might
stroke
diabetes (κ=0.93) and
have been due to
stroke (κ=0.85).
participation of the study
participants in an earlier
screening program.
Chronic non-specific
High agreement for
Information from general
lung disease, cardiac
diabetes (κ=0.85),
practitioners was considered
disease, peripheral
moderate agreement for
to be an “alloyed”, not true
atherosclerotic disease, neoplasm and cardiac
gold-standard. The sample
cerebrovascular
disease (κ=0.64 and κ=0.69 chosen for this study was
disease, diabetes,
respectively) was observed, relatively sicker than the
malignant neoplasm,
whereas low agreement for parent study‟s sample,
osteoarthritis/rheumatoi osteoarthritis/rheumatoid
which might have
84

High agreement was noted
for conditions like
diabetes, hypertension,
myocardial infarction
(κ=0.78, 0.78, 0.77
respectively), whereas
lower agreement was found
for conditions like lower
back pain (κ=0.42).

Author
(year)

Okura et al.
(2004) [15]

Population and GoldSample size
standard

General
population
(Olmstead
county
residents)

Medical
records

Conditions/Features
Evaluated

Results/ Key Findings

d arthritis

arthritis (κ=0.31) and
peripheral atherosclerotic
disease (κ=0.38).

Heart failure, diabetes,
myocardial infarction,
hypertension, stroke
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Comments

contributed to increase in
awareness regarding the
medical condition present in
participants. Findings of the
study indicate that accuracy
for recall is higher for
chronic conditions that have
a well defined diagnostic
criteria and are easily
understood by patients,
whereas conditions with
diagnostic criteria that are
not easily understood by
patients, have lower recall
rates. Also, in this cohort it
was observed that patients
had higher recall for those
chronic conditions that they
perceived to be life
threati9nging to them over
those conditions that are
generally associated with
old-age and are not
considered life threatening
(example, arthritis)
Good agreement was found Good study design. Using
for diabetes (κ=0.76),
randomly selected
hypertension (κ=0.75),
population based sample
myocardial infarction
minimized selection bias.
(κ=0.80) and stroke
Authors were able to justify

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

(n=2,037)

Paganini-Hill
et al. (1982)
[16]

Elderly women
cohort (n=334)

Medical
records,
Pharmacy
records

Gallbladder disease,
hypertension, diabetes,
benign breast disease,
hysterectomy,
oophorectomy

Smith et al.
(2008) [17]

Military cohort
(n=37, 798)

Medical
records

38 medical conditions;
ranging from
hypertension, chronic
bronchitis, kidney
failure, to sinusitis,
depression, asthma etc.
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Results/ Key Findings

Comments

(κ=0.71), whereas lower
agreement was found for
heart failure (κ=046).

the use of medical records
as the „gold-standard‟.
Findings of the study also
illustrate that accuracy for
recall is higher for chronic
conditions that have a well
defined diagnostic criteria
and are easily understood by
patients, whereas conditions
with diagnostic criteria that
are not easily understood by
patients, have lower recall
rates.
Good study design (casecontrol).

Good overall agreement
was observed for most
conditions. Highest
agreement was observed
for hysterectomy (κ=0.96)
and lowest agreement was
observed for benign breast
disease (κ=0.63).
Typically good agreement
was noted for chronic
conditions, for example,
53.5% positive agreement
was found for hypertension
and only 1.4% positive
agreement was found for
migraine.

The study cohort was
relatively young and
physically active in this
study. The results suggested
that use of electronic
medical records might be
appropriate to estimate
prevalence of conditions in
a sample.

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Comments

Simpson et
al. (2004)
[20]

Elderly women
(n=1, 002)

14 medical conditions;
ranging from hip
fracture, Parkinson‟s
disease, to
osteoporosis, arthritis

Overall good agreement wt
was found for most
conditions. Highest
agreement was found for
hip fracture (κ=0.96) and
lowest agreement was
found for arthritis (κ=0.24).

Good study design. Used
multiple sources to compare
self-repotted information.
Used random sampling, thus
minimizing bias.

Tisnado et al.
(2006) [26]

Cohort of
patients
enrolled in
managed care
organization
(n=1,270)

Medical
records,
laboratory
and physical
test results,
physician
questionnair
e
Medical
records,
patient selfreport

Diagnosis of medical
conditions (cancer,
diabetes, asthma etc.),
medication use,
counseling and
referrals, clinical
services delivered.

Overall good level of
agreement was observed
for diagnosis of conditions
and medication use but for
clinical services,
counseling and referrals
lower level of agreement
was observed.

Miller et al.
(2008) [63]

Cohort of
patients from
the Medicare
Health
Outcomes
Survey (HOS)
who were also
eligible for
Veterans
Affairs (VA)
care
(n=7,953)
Cohort of low-

VA medical
records

10 chronic conditions
(diabetes, hypertension,
chronic lung disease,
arthritis, angina,
congestive heart
failure, myocardial
infarction, stroke, and
cancer).

Good level of agreement
was observed for most
conditions (75%). Highest
agreement was observed
for diabetes (κ=0.82) and
lowest for chronic low
back pain (κ=0.33).

Good study design; used
bootstrapping to account for
representation of patients in
multiple items in
questionnaire. Authors
provide a good explanation
of using two gold standards
and potential sources of
disagreement.
Nice study design. The
authors were able to explain
the possible sources of
disagreement.

PACE

Ten major therapeutic

Overall high levels

Caskie et al.
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Use of „brown bag‟ for

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Comments

(2004) [68]

income elderly
patients

(Pharmaceut
ical
Assistance
Contract for
the Elderly)
program‟s
pharmacy
records

agreement was noted for
agreement for self-reported
medication use when
compared with pharmacy
data. Highest agreement
was observed for
cardiovascular drugs
(κ=0.83).

collecting self-reported data
regarding medication use is
noteworthy and eliminates
chances of biases.

West SL et
al. (1995)
[28]

Cohort of
patients
enrolled in
managed care
organization
(n= 560)

Pharmacy
dispensation
database

classes of drugs;
ranging from
antihistamines, antiinfective, to
cardiovascular,
gastrointestinal and
CNS agents. Specific
selected classes of
drugs within two major
classes (cardiovascular
and CNS agents) were
also included.
Use of nonsteroidal
anti-inflammatory
drugs and
noncontraceptive
estrogens.

Cohort of
patients
enrolled in
managed care
organization
(n= 270)
Ferrante et al. Cohort of
(2008) [44]
patients
enrolled in the
SCOPE
(Supporting

Pharmacy
records data

Van den
Brandt et al.
(1991) [29]

Medical
record

Fair agreement in recalling
any use of NSAID was
noted (41%) of which 30 %
could recall name of the
medication, while only
15% recalled both name
and dose of the medication.
Prescription medication Moderate agreement
use for general use.
(61.2%) was observed.
Highest agreement was
noted for cardiovascular
drugs (65.9%).

Good study design. Use of
pharmacy dispensation
database as gold standard
provided accurate
estimation of drug use.

Cancer related risk
factors, screening tests
and counseling

The study provides good
information on the various
factors related to level of
agreement in a cohort of
cancer patients. Use of
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Highest agreement was
noted for self-reported
information self-reported
information regarding
diagnosis of cancer (96%),

Nice study design; use of
population level data
provided enough power for
analysis.

Author
(year)

Population and GoldSample size
standard

Westbrook et
al. (1998)
[36]

Colorectal
Cancer
Outcomes
through
Participatory
Enhancements)s
tudy
Cohort of
Medical
patients with
records
dyspepsia

Bergmann et
al. (1998)
[45]

Cohort of
participants in
the American
Cancer
Society‟s CPSII study
(n=65, 582)

Population
based
cancer
registry data

Hall et al.
(2004) [46]

Cohort of
Medical
patients
records
enrolled in three
health

Conditions/Features
Evaluated

Self-reported diagnosis
of dyspepsia and its
management

Self-reported cancer
diagnosis

Self-reported
information on digital
rectal examination,
prostate specific
89

Results/ Key Findings

Comments

whereas agreement for
self-reported smoking
cessation counseling was
low (41%)

medical records as the goldstandard was appropriate
considering the outcomes of
interest.

Overall poor agreement
was observed. Low
agreement was noted for
factors like duration of
dyspepsia (κ=0.34) and
number of medication
taken (κ=0.28 and κ=0.31
for medications taken
before and after endoscopy
respectively).
Level of agreement for
self-reported diagnosis of
cancer varied by site.
Highest sensitivity was
noted for cancer for breast
(0.91), prostate (0.90) and
lung (0.90), whereas lowest
agreement was noted for
cancer of rectum (0.16).
Overall good agreement
was found for PSA test,
sigmoidoscopy, and
colonoscopy (κ=0.40-

Results of the study
illustrate the issue of lack of
knowledge about the nature
of conditions and
misunderstanding the
diagnoses of their
conditions.

Good study design. Use of
population level study
cohort and state level
registry data ensured
sufficient power for
analysis.

--

Author
(year)

Mukerji et al.
(2007) [47]

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

maintenance
organization
(HMOs)
(n=2,1 30)
Cohort of
patients having
head and neck
cancer
(n=458)

antigen (PSA) test,
fecal occult blood tests,
sigmoidoscopy, and
colonoscopy
Self-reported
comorbidities due to
cancers other than head
and neck cancer

0.80).

Medical
records

Goebeler et
al. (2007)
[49]

Cohort of
elderly patients
aged 90 years
and older
(n=209)

Medical
records

Self-reported medical
history

St. Sauver et
al. (2005)
[38]

Cohort of
patients
enrolled in
Mayo Clinic

Medical
records

Self-reported
information on
cardiovascular disease
(CVD) and it‟s risk
factors

Solomon et
al. (2007)

Cohort of
patients

Medical
records

Self-reported
information on
90

Good agreement was found
in general. Highest
agreement t was found for
diabetes (κ=0.89) and
lowest for arthritis
(κ=0.11).
Overall moderate to fair
level of agreement was
observed for most
conditions. Agreement was
highest for Parkinson‟s
disease (κ=0.74) and
lowest for depression
(κ=0.11).
Level of agreement varied
for various CVD
conditions. Highest
agreement was found for
high blood pressure
(77.9%) and lowest
agreement was found for
medical problems related
to peripheral arteries
(31%).
Agreement varied by drug
class and time of use, for

Comments

--

Good study design. The
study illustrates various
predictors that can influence
recall in elderly population
for chronic conditions.

The study illustrates that
recall rates are higher for
chronic diseases.

--

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

[50]

enrolled in the
BRASS
(Brigham
Rheumatoid
Arthritis
Sequential
Study) study
Cohort of end
stage renal
disease (ESRD)
in CHOICE
(Choices for
Healthy
Outcomes in
Caring for Endstage renal
disease)study
(n=965)

rheumatoid and
medication use

example agreement for
current use for
methotrexate was (κ=0.96)
whereas agreement for past
use of methotrexate was
(κ=0.13).

Self-reported
information on eight
comorbid conditions :
congestive heart
failure, myocardial
infarction,
cerebrovascular
disease, angioplasty or
coronary artery bypass
graft surgery,
hypertension, diabetes,
chronic obstructive
pulmonary and cancer
Self-reported
information on
patients‟ illness history,
surgery and medication
use.

Highest agreement was
recorded for diabetes
(κ=0.93) and lowest
agreement was recorded
for chronic obstructive
pulmonary disease
(κ=0.20).

The study illustrates the
concern about low
agreement for those
conditions that do not have a
clear diagnostic criteria and
high agreement for those
conditions that have higher
awareness among a
particular cohort.

Overall substantial
agreement was found
(κ=0.69). Highest
agreement was found for
skin cancer (κ=0.58) and
lowest agreement was
found for pneumonia
(κ=0.27).
Level of agreement varied
by conditions. Highest

The authors contest the
issue of questionnaire
design and suggest that
„open-ended questions‟
might contribute towards
higher agreement.

Merkin et al.
( 2007) [51]

Medical
records,
physician
report

Boissonnault
et al. (2005)
[52]

Cohort of
outpatient
orthopedic
surgery
candidates
(n=100)

Medical
records,
physician
report

Iversen et al.
(2007)

Cohort of agesex stratified

Medical
records

Self-reported
information regarding
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Comments

--

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

sample
(n=2, 318)

chronic respiratory
disease and health
services utilization

Skinner et al.
(2005) [48]

Cohort of
patients from
the Veterans
Health Study
(VHS)
(n=402)

Medical
records

Hessol et al.
(2001) [103]

Cohort of
women enrolled
in WIHS
(Women‟s
Interagency
HIV study)
study
(n=339)

County
level AIDS
surveillance
data

Results/ Key Findings

Comments

agreement was observed
for pulmonary tuberculosis
(κ=0.88), lowest agreement
was observed for chronic
bronchitis (κ=0.10).
Self-reported
High agreement was noted Findings of this study
information about five
for diabetes (κ=0.84) and
indicate that recall rates are
chronic medical
hypertension (κ=0.70).
higher for chronic
conditions: diabetes,
conditions that have well
hypertension,
defined diagnostic criteria
obstructive lung
than those that have
disease, chronic low
ambiguous diagnostic
back pain, osteoarthritis
criteria. Also, the study
of knee
illustrates the issue of
misunderstanding of the
diagnosis by patients that
can possibly contribute
towards lower agreement
Self-reported
information about
diagnosis of AIDS and
AIDS related
conditions.
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Fair agreement was found
for self-reported
information about AIDS
diagnosis and registry data
(73%).

The level of agreement
varied by specific
conditions. This could have
occurred because of
inaccurate information
about non-AIDS related
conditions from the patients,
which they might have
thought are AIDS related,
and are not present in
registries.

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Comments

Kropp et al.
(2007) [71]

Cohort of
patients
enrolled in the
MARIE
(Mammacarcin
oma Riskfactor
Investigation)
study
(n=449)
Cohort of
patients
enrolled in an
HMO and
VAMC and
with a diagnosis
of hypertension
(n=200)
Cohort of
patients
enrolled in the
Kuopio
Osteoporosis
Study
(OSTPRE)
(n=11,377)

Prescription
records
from
physicians

Self-reported hormone
therapy use

Good agreement was
observed (88.2%) for selfreported hormone therapy
compared with prescription
records form physicians.

--

Pharmacy
prescription
data

Self-reported
information about
missing
antihypertensive
medication

Poor agreement was noted
for self-reported
compliance with
antihypertensive therapy
(κ=0.12).

--

National
level
prescription
database

Self-reported
information about
hormone therapy use

Good agreement (97.6%)
was observed for selfreported hormone therapy
use when compared with
national level prescription
database.

Cohort of
patients having
a diagnosis of

National
level
prescription

Self-reported
information about
prescription

Good overall agreement
was observed for most
psychotropic drugs.

Good study design. The
specific questions asking for
self-reported hormone
therapy use were clear and
comprehensive. The
questions also asked for
names of hormone therapy
medications, which
contributed to high
specificity.
Good study design using of
national level database.
Quite contrary to general

Wang et al.
(2003) [106]

Sandini et al.
(2008) [102]

Haukka et al.
(2007) [69]
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Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Comments

schizophrenia
(n=905)

database

psychotropic
medication

Highest agreement was
observed for lithium
(κ=0.96) and
antipsychotics (κ=0.87).

Nielsen et al.
(2008) [70]

Cohort of
patients from
the Danish
health survey
for the year
2000
(n=16,688)

National
level
prescription
records

Self-reported
information regarding
prescription medication
use.

Sjahid et al.
(1998) [66]

Cohort of
patients from
the Rotterdam
elderly Study
(n=3,365)

Pharmacy
data

Self-reported
information regarding
cardiovascular drugs

High agreement was
observed for prescription
drugs used for longer
duration (chronic), like
insulin and its analogues
(κ=0.78) and
cardiovascular drugs
(κ=0.84).
High overall agreement
was observed (80.6%).
Highest agreement was
noted for β-adrenoceptor
class (κ=0.97).

assumption that agreement
for psychotropic
medications is lower, the
study had high agreement
for these drugs. Participants
were asked to bring their
medication prescription for
psychotropic medications,
which might have resulted
in high overall agreement
rates in this population.
Nice study design. The
findings of the study
indicated higher recall rates
for prescription drugs used
for long duration or for
chronic conditions, and
lower recall rates for drugs
used occasionally.
The findings indicated that
agreement was good for
drugs that are used
repetitively /regularly, than
those that are used
intermittently. Also in this
dataset, the authors noted
that agreement was good for
drugs that are „prescription
only‟ over those that are
also available over-the-
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Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Curtis et al.
(2006) [73]

Cohort of
patients using
medication for
chronic
glucocorticoid
(n=2,363)

Pharmacy
data from a
national
MCO

Substantial to moderate
agreement was found for
the four medications,
highest being for
alendronate (κ=0.80).

Løkkegaard
et al. (2004)
[72]

Cohort of
Danish nurses
(n=2,666)

Brown et al.
(2007) [67]

Cohort of
patients from
the Adverse
Childhood
Experiences
(ACE) study
(n=4,308)

National
level
prescription
reimbursem
ent database
Pharmacy
claims data

Self-reported
information regarding
use of four osteoporosis
medications
(alendronate,
risedronate, calcitonin,
raloxifene)
Self-reported
information about
hormone replacement
therapy (HRT)
Self-reported
information about
exposure to lipidlowering drugs

Overall high accuracy rate
was found for self-reported
HRT use. For current HRT
use sensitivity was 78.4%
and specificity was 98.4%.
Good agreement was
observed for self-reported
lipids lowering medication
use (κ=0.67); 96% cases
were concordant.

Comments

counter.
Good study design. The
authors observed high
agreement for medications
with characteristic dosing
instructions than for those
that have less exclusive
dosing instructions.
Good study design. Study
sample used for the study
(nurses) might have
contributed towards higher
degree of agreement.
--

STUDIES CONDUCTED AMOMG PREGNANT WOMEN
Bryant et al.
(1989) [30]

Cohort of
pregnant
women (n=
202)

Medical
records

Short term illnesses and In general lower level of
medication use during
agreement was observed
pregnancy
for most conditions and
medication use. Highest
agreement was noted for
prescription medication use
(κ=0.48).
95

Used two groups of women:
still pregnant and
postpartum. Comparison of
results among these two
groups provided nice insight
into issues related to recall
of events and minimized

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Webb et al.
(2003) [32]

Cohort of
pregnant
women (n= 74)

Laboratory
urine
cotinine
level results

Self-reported smoking
behavior

The results of the study
showed high level of
disagreement. While
laboratory results showed
63% of the women smoked
during pregnancy, only
25% of the women gave
correct self-reported
information about
smoking.

Ford et al.
(1997) [33]

Cohort of
pregnant
women (n= 4,
857)

Laboratory
Self-reported smoking
serum
behavior
cotinine
level results,
obstetrics
records

Ernhart et al.
(1988) [34]

Cohort of
pregnant

Retrospectiv Self-reported
ely collected information regarding

There was substantial level
of discrepancy between
self-reported information
about smoking behavior
and laboratory serum
cotinine level results. Only
19.2% of the women gave
accurate information about
smoking in the first
trimester, whereas form
laboratory results it was
found 31.3% of the women
smoked during first
trimester.
There was significant
discrepancy between the
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Comments

biases related to it.
Use of urine cotinine levels
provided a good measure to
validate self-reported
information. Also the
population sample used
(low-income) provided good
insight on the characteristics
of pregnant women in this
population, thereby
providing knowledge about
how to effectively plan
smoking cessation programs
in such a population.
Identical results for level of
agreement in self-reported
information and obstetric
records (which were
inconsistent with lab results)
to compare the revealed that
self-reported information
about smoking status
provided by pregnant
women to their physicians
may be inaccurate, and
should be validated by a
biochemical test.
Long recall interval (5
years) might have

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Comments

women (n=
238)

information
regarding
alcohol
consumptio
n during
pregnancy
Laboratory
serum/urine
cotinine
level results

alcohol consumption
during pregnancy

two data sources. More
women reported positive
smoking during pregnancy
when asked retrospectively
than when they were asked
during pregnancy.
Good level of agreement
was observed.
Concordance was found for
self-reported information
from 84.6% women when
compared with their
laboratory serum/urine
cotinine levels.

contributed towers lowering
the level of agreement
between the two data
sources.

Laboratory
serum
cotinine
level results
Newborn
baby‟s
meconium
analysis
results
Patients‟
Michigan
Alcoholism
Screening
Test
(MAST)

Self-reported smoking
behavior

High level of agreement
was found for data sources
(κ=0.83).

Self-reported drug use

Concordant results were
obtained in 66 % cases.

Use of meconium analysis
results is a novel method to
validate self-reported
information about drug use.

Self-reported
information about
alcohol and drug use
during pregnancy
(collected twice
prenatally and 13

Women reported higher
alcohol and drug use in
their retrospective selfreports, than when they
were asked during their
pregnancy. Also, these

Use of MAST scores for
validating self-reported
alcohol and drug use is
unique. These measures also
revealed maternal
characteristics for high

Klebanoff et
al. (2001)
[35]

Cohort of
pregnant
women (n=
105)

Klebanoff et
al. (1998)
[42]

Cohort of
pregnant
women
(n=452)
Cohort of
women who
had just given
birth
(n=8,527)
Cohort of
pregnant
women
(n=361)

Lester et al.
(2001) [107]

Jacobson et
al. (1991)
[81]

Self-reported smoking
behavior
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The study sample wad
derived from another study
for calcium intake and preeclampsia and was not
focused on smoking
behavior, which might have
contributed to moderate
agreement between the two
sources of data.
--

Author
(year)

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

scores

months after birth of
their babies)

women had higher MAST
scores.

North
Jutland
Prescription
database

Self-reported use of
prescription medication
use

Olesen et al.
(2001) [40]

Cohort of
pregnant
women enrolled
in the DNBC
(Danish
National Birth
Cohort) survey
(n=2,041)

Fox et al.
(1989) [80]

Cohort of
Saliva
pregnant
thiocyanate
women enrolled levels
in a randomized
clinical trial of a
smoking
cessation
program
(n=700)

Self-reported smoking
status and alcohol
consumption during
pregnancy.

Hessol et al.
(2004) [79]

Cohort of
pregnant

Behavioral factors
(alcohol use, tobacco

Medical
records
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Comments

alcohol consumption during
pregnancy like, depression
and a history of alcohol
abuse.
In general, higher recall
The results of the study
rates were observed for
suggested higher recall rates
medications taken recently for chronically used drugs.
and those taken for longer
The authors were able to
duration. For example,
describe potential biases that
recall rate was 43% for
could have occurred due to
medications taken 120 days the data sources used for
before the interview and
comparison.
49% for medication taken
60 days before the
interview.
Identical rates of recall
Self-reported information
were observed for both the was collected twice. The
treatment group and the
results reveal that pregnant
control group. The level of women provide similar
agreement of smoking
information about smoking
status for the treatment
status at any time interval
group was κ=0.61 and
during their pregnancy.
κ=0.57 for the control
group. For alcohol use it
was κ=0.52 for the
treatment group and
κ=0.55 for the control
group.
Lower agreement for
Good study design. The
alcohol use during
study illustrates the

Author
(year)

Britton et al.
(2004) [77]

Population and GoldSample size
standard

Conditions/Features
Evaluated

Results/ Key Findings

Comments

women in the
Latina Health
Project
(n= 321)

use, use of prenatal
vitamins) and medical
factors (anemia,
gestational diabetes,
hypertension).

pregnancy (κ=0.37) and
prenatal vitamin use
(κ=0.09) was observed.
Agreement for gestational
diabetes (κ=0.83) and
hypertension (κ=0.68) was
the highest.
Disconcordance was found
in 34.7% of cases where
active (current) smokers
reported no smoking, and
for 10.4% of women who
reported active smoking
but their urine cotinine
levels.

influence of language on
recall accuracy.

Cohort of
pregnant
women enrolled
in a smoking
cessation
program
(n= 94)

Laboratory
urine
cotinine
level results

Self-reported smoking
status
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Awareness to quit smoking
among pregnant women
enrolled in the smoking
cessation program might
have added to increase in
agreement.

APPENDIX 2: ‘SMART’ STUDY QUESTIONNAIRE
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GENERAL INFORMATION
1. Date of interview:

__ /__ /__ (month/day/year)

2. Location of interview: _____________________________________
3. Prenatal care provider‟s last name: ___________________________
4. Examiner‟s last name: _____________________________________
5. Patient‟s phone number: ___________________________________

DEMOGRAPHIC / LIFESTYLE INFORMATION
6. How old are you? ________________ (years)
7. What is your marital status now?
[ ] Single, never married
[ ] Married, living with spouse
[ ] Not married, but living with partner
[ ] Separated from spouse
[ ] Divorced
[ ] Widowed

8. Are you Hispanic, Latino or of Spanish descent?

[ ] Yes [ ] No

9. How do you describe yourself: (check all that apply)
[ ] White, non-Hispanic or

[ ] White, Hispanic

[ ] Black or African American
[ ] American Indian or Alaskan Native - Please specify [ ] tribe or [ ] pueblo
[ ] Asian or Asian American or Pacific Islander
[ ] Some other group(s) – please specify: ______________________________________
[ ] Prefer not to report

10. What is the highest level in school you have completed?
[ ] Less than high school graduate
[ ] High school graduate or GED
[ ] Some college or vocational school
[ ] College degree
[ ] Masters, doctorate or professional degree

101

11. What is your health insurance status?
[ ] No insurance
[ ] Employer-based insurance
[ ] Self-purchased insurance
[ ] Medicaid
[ ] Other public insurances ( [ ] Indian Health Service, [ ] VA, [ ] First Choice,
UNM/UNMCARE)

11a. Does your insurance cover prescription drugs?
12. Were you born in the Unites States?

[ ] Yes [ ] No
[ ] Yes [ ] No

If „Yes‟, go to question 13. If „No‟, please answer questions 12a and 12b.
12a. Did you move to the United States: [ ] With your parents when you were a child
[ ] When you were an adult (≥18 years old)
12b. How long have you lived in the United States: ____________ years

13. What language do you mostly use at home?
[ ] English
[ ] Spanish
[ ] Some other language – specify:__________________________________
14. Do you currently smoke cigarettes or use tobacco?
[ ] Yes

[ ] No

14a. How many cigarettes do you

14b. Have you smoked >100

usually smoke in one day? _________ cigarettes in your life?

[ ] Yes
14c. When did you stop smoking?
question

[ ]No
* Go to the next

[ ] Before I became pregnant
[ ] After I realized that I was pregnant

15. Have you ever drank alcohol in your life (e.g., beer, wine, hard liquor, mixed drinks)?
[ ] Yes
[ ] No
If „yes,‟ continue to questions 15a and 15b. If „no,‟ continue to 21a.
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15a. How many drinks does it take before you begin to feel the first effect of alcohol?
________
15b. How many drinks typically can you hold before passing out or falling asleep?
________
a. What was the first day of your last menstrual period ___/___/___ (mm/dd/yy)?
I would like you to think back to that period and tell me about your drinking at that time.
16. During a month or so around your last menstrual period before you got pregnant, how
many times did you drink 4 or more drinks on one occasion? __________
Now I want you to think of 12 months before you got pregnant (a year prior to your LMP)
17. During the year before you got pregnant, did close friends or relatives worry or complain
about your drinking habits?
[ ] Yes [ ] No
18. During the year before you got pregnant, did you ever take a drink first thing in the morning
to get yourself going?
[ ] Yes [ ] No
19. During the year before you got pregnant, did a friend or family member tell you about things
you said or did while you were drinking that you could not remember?
[ ] Yes [ ] No
20. During the year before you got pregnant, did you feel you need to cut down on your drinking?
[ ] Yes [ ] No

[TWEAK High: ______; TWEAK Hold: ______]
MEDICAL AND REPRODUCTIVE HEALTH

21a. What was your pre-pregnancy weight? ____________ pounds
21b. What was your pre-pregnancy height? ____________ feet/inches
[Researcher Calculated BMI: _______________ ]
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22. Do you have a medical condition or problem that requires ongoing, periodic, or
occasional treatment?
[ ] Yes [ ] No

22a. If yes, check all that apply:
[ ] Hypertension (high blood pressure)

[ ] Depression

[ ] Diabetes: [ ] Gestational [ ] Type I [ ] Type II

[ ] Anxiety

[ ] Seizure disorder (i.e., epilepsy)

[ ] Migraine headaches

[ ] Thyroid disorder

[ ] Rheumatoid arthritis

[ ] Asthma or allergies

[ ] Heart disease

[ ] Cancer

[ ] Hepatitis

[ ] Other(s) problem - specify: ______________________________________________
If „Yes‟ to diabetes, please answer questions 23 and 24. If „No‟, skip to question 26.
If „Yes‟ to asthma, please answer question 25. If „No,‟ skip to question 26.

23. Have you ever had gestational diabetes?
[ ] Yes, in a previous pregnancy only
[ ] Yes, in the current pregnancy only
[ ] Yes, in a previous pregnancy and in the current pregnancy
[ ] No, never had gestational diabetes
[ ] No, never been pregnant before

24. How likely do you think uncontrolled high blood sugar could harm your developing
baby by causing birth defects or other serious health problems? (circle one number)
1
Not at all
likely to harm

2
Unlikely
to cause harm

3
Somewhat
likely to harm

4

5

Likely Very likely
to harm to cause harm

25. How likely do you think asthma exacerbations requiring hospitalization or
unscheduled clinic visits could harm your developing baby? (circle one number)
1
Not at all
likely to harm

2
Unlikely
to cause harm

3
Somewhat
likely to harm

4

26. Did you plan to get pregnant with this child?
[ ] Yes

[ ] No, not now

[ ] No, not at any time
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5

Likely Very likely
to harm to cause harm

27. Were you or your partner doing anything to try to prevent becoming pregnant with
this child?
[ ] Yes

[ ] No

27a. If Yes, which method were you using?
[ ] Condoms

[ ] Diaphragm

[ ] Withdrawal [ ] IUD

[ ] Birth control pills
[ ] Rhythm

[ ] Depo Provera, Implanon or Norplant [ ] Other: _____________________

28. Did you take any fertility drugs to help you get pregnant with this child, like Clomid,
Metrodin, Fertinex, or Pergonal?
[ ] Yes

[ ] No

28a. If Yes, which drugs did you use? __________________________________
29. Have you or members of your immediate family (mother or sisters) or the immediate
family of your baby‟s father had any babies with birth defects (including babies that
might not have survived)?
[ ] Yes

[ ] No

* If „No‟, go to question 30. If „Yes‟, please specify:

Down syndrome

[ ] Yes

[ ] No

Cleft lip or palate

[ ] Yes

[ ] No

Neural tube defect

[ ] Yes

[ ] No

Cystic fibrosis

[ ] Yes

[ ] No

[ ] Yes

[ ] No

[ ] Yes

[ ] No

Heart defect
Other

If “Yes,” please specify:_________________________________
30. What was the first day of your last menstrual period?__

__ / __ __ /__ __ (mm /

dd / yy)

31. What is the date your baby is due to be born: ___ ___ / ___ ___ / ___ ___ (mm / dd / yy)
31a. What is the gestational age of your baby? ___________ weeks
31b. How was your due date estimated? By:
[ ] Last menstrual period
[ ] Ultrasound
[ ] Physical exam
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32. How many times (including this pregnancy) have you been pregnant?
_____________
If this is the 1st pregnancy put “1”for q. 32 and “0” for questions 33-37 & skip to
question 37.
33. How many live-born children have you had? ___________
If no live-born children or this is the first pregnancy, then put “0”
34. Have you ever had a miscarriage (<20 wk of gestation). If yes, how
many?_______
If never had a miscarriage, put “0”
35. Have you ever had a stillborn child (≥ 20 wk of gestation). If yes, how
many?______
If never had a stillborn child, put “0”
36. Have you ever had a pregnancy terminated? If yes, how many?_______
If never had a termination, put “0”
37. Have you ever had an ectopic pregnancy. If yes, how many?_________
If never had an ectopic pregnancy, put “0”
38. For this pregnancy, how many weeks after your last menstrual period did you first
think you were pregnant? _________
39. For this pregnancy, how many weeks after your last menstrual period did you first go
to see a doctor or other health care provider or go to the clinic for prenatal care?
__________
40a. Have you had any complications in this pregnancy so far?
(* Please check yes or no for each complication)
- Bleeding
- High blood pressure
- Diabetes
- Other

[ ] Yes [ ] No
[ ] Yes [ ] No
[ ] Yes [ ] No
[ ] Yes [ ] No

40b. If “other”, please specify: ____________________________________
41. Have you experienced morning sickness during this pregnancy? [ ] Yes
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[ ] No

USE OF MEDICATIONS AND SUPPLEMENTS DURING PREGNANCY

42. Did you take a multivitamin regularly (4 times a week or more) during the month
before your last menstrual period?
[ ] Yes

[ ] No

43. Have you taken any VITAMINS regularly (4 times/week or more) since you became
pregnant?
43a. [ ] Yes, multivitamins [ ] Yes, a single vitamin
[ ] No
If „Yes,‟ answer questions 43b-43e.
43b.

[ ] Prescription

[ ] OTC

43c.

[ ] Brand name: _______________________________

43d. When did you start taking vitamins?
______________ (mm/dd/yy) ____________ (gestational weeks)
43e. How many days during the last week did you take vitamins? ________
(days/week)

44a. Have you taken any DIETARY SUPPLEMENTS (including iron supplements) or
HERBAL PRODUCTS on a regular basis since your last menstrual period?
[ ] Yes

[ ] No

44b. If „Yes‟ to herbal products, please specify: [ ] Herbs
[ ] Tablets or capsules
[ ] Teas
[ ] Other: ______________________
44c. How often do you take them? [ ] Regularly: _____ times per ______ or [ ] When I
feel sick
Please specify any other dietary supplements or products and reason for taking it:

Product 1:_______________ Reason/Condition: ______________________
Product 2: _______________Reason/Condition: ______________________
Product 3: _______________Reason/Condition: ______________________
44d. Have you had any cravings for non-food items or really “strange” foods?

[ ] Yes

[ ] No
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If „yes‟ what did you crave, do you eat it, and how often do you eat it?

Item 1: ______________________ Eat it? [ ] Yes [ ] No; How often?
Item 2: ______________________ Eat it? [ ] Yes [ ] No; How often?
Item 3: ______________________ Eat it? [ ] Yes [ ] No; How often?

45. Have you ever taken any recreational drugs?
[ ] Yes [ ] No
If „Yes‟ please specify the recreational drug name(s) and when it was used:
Check if taken:
[ ] Marijuana/Hashish:

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

[ ] Heroin:

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy
Have you gone through methadone treatment?
[ ] Never
[ ] Completed treatment before pregnancy
[ ] Undergoing treatment during current pregnancy

[ ] Cocaine/Crack:

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

[ ] Inhalants (glue, solvent): [ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy
[ ] Methamphetamines:

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

[ ] Other: ____________

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

[ ] Other: ____________

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

46. Did you discuss the safety of medications in pregnancy with any health care provider
(physician, nurse-midwife, physician assistant, or pharmacist)?
[ ] Yes
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[ ] No

47a. Have you had any vaccinations since your last menstrual period?
[ ] Yes
47b. If Yes to vaccinations, please specify:

[ ] No

[ ] Flu
[ ] Other: ___________________

48. Have you taken any medications PRESCRIBED by your doctor or any other health
care provider since your last menstrual period, even if you stopped taking them once you knew
you were pregnant?
[ ] Yes

[ ] No

If „Yes‟ please specify the medication name, reason for taking it, and your perception of how
likely it is that this medication might be harmful for your baby if taken during pregnancy:

a. Medication1:_________________________ Indication: ________________________
How likely do you think it is that this medication could harm your developing baby by
causing birth defects or other serious health problems: (circle one number)
1

2

Not at all
likely to harm

Unlikely
to cause harm

3
Somewhat
likely to harm

4

5

Likely Very likely
to harm to cause harm

b. Medication2:___________________________ Indication: ______________________
How likely is it that this medication could harm your developing baby by causing birth
defects or other serious health problems: (circle one number)
1

2

Not at all
likely to harm

Unlikely
to cause harm

3
Somewhat
likely to harm

4
Likely
to harm

5
Very likely
to cause harm

c. Medication 3:___________________________ Indication: ____________________
How likely is it that this medication could harm your developing baby by causing birth
defects or other serious health problems: (circle one number)
1
Not at all
likely to harm

2
Unlikely
to cause harm

3
Somewhat
likely to harm

4

5

Likely Very likely
to harm to cause harm

d. Medication 4:___________________________ Indication: ____________________
How likely is it that this medication could harm your developing baby by causing birth
defects or other serious health problems: (circle one number)
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1

2

3

Not at all
likely to harm

Unlikely
to cause harm

Somewhat
likely to harm

4
Likely
to harm

5
Very likely
to cause harm

e. Medication 5:___________________________ Indication: ____________________
How likely is it that this medication could harm your developing baby by causing birth
defects or other serious health problems: (circle one number)
1
Not at all
likely to harm

2

3

4

Unlikely
Somewhat
to cause harm likely to harm

5

Likely Very likely
to harm to cause harm

49. During this pregnancy, did you take any OVER-THE-COUNTER MEDICATIONS (sold
without prescription)?
[ ] Yes

[ ] No

Check all medications that you have actually taken since your last menstrual period, even if you
stopped taking them once you knew you were pregnant. Then for medications you took since
pregnancy, please specify your perception of how likely each medication is to cause birth defects
or other problems for your baby.

Pain/Fever Medications:
Rate all medications:
Not at all
Check if taken:

likely
to harm

Unlikely to
cause harm

Somewhat
likely to harm

Likely
to harm

Very
likely
to harm

[ ] Acetaminophen (Tylenol) 1

2

3

4

5

[ ] Aspirin

1

2

3

4

5

[ ] Ibuprofen (Advil, Motrin) 1

2

3

4

5

[ ] Ketoprofen (Orudis)

1

2

3

4

5

[ ] Naproxen (Aleve)

1

2

3

4

5

[ ] Other medication –

1
2
3
4
specify:
________________________________________________________________

5

Nasal Decongestants, Allergy, Cough Medications:
Rate all medications:
Check if taken:

Not at all
likely
to harm

Unlikely to
cause harm

Somewhat
likely to harm

Likely
to harm

Very
likely
to harm

[ ] Chlorpheniramine

(Chlor-Trimeton)

1

2

3

4

5

[ ] Benadryl

1

2

3

4

5

[ ] Pseudoephedrine (Sudafed)

1

2

3

4

5
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[ ] Claritin, Zyrtec

1

2

3

4

5

[ ] Other medication –

1

2

3

4

5

specify: _________________________________________________________________
Antidiarrheal Medications:
Rate all medications:
Not at all
Check if taken:

likely
to harm

Unlikely to
cause harm

Somewhat
likely to harm

Very
likely
to harm

Likely
to harm

[ ] Kaopectate, Pepto Bismol 1

2

3

4

5

[ ] Loperamide (Imodium)

1

2

3

4

5

[ ] Other medication –

1

2

3

4

5

specify: _________________________________________________________________
Heartburn, Dyspepsia, Antiemetic, Laxative Medications:
Rate all medications:
Check if taken:

Not at all
likely
to harm

Unlikely to
cause harm

Somewhat
likely to harm

Very
likely
to harm

Likely
to harm

[ ] Maalox, Mylanta Gas

1

2

3

4

5

[ ] Tums

1

2

3

4

5

Axid, Pepcid

1

2

3

4

5

[ ] Colace

1

2

3

4

5

[ ] Correctol, Dulcolax, Ex-Lax 1

2

3

4

5

[ ] Senna, fiber products

1

2

3

4

5

[ ] Unisom
[ ] Other medication –

1
1

2
2

3
3

4
4

5
5

[ ] Tagamet, Zantac,

specify: _________________________________________________________________
Antifungal Medications (taken for vaginal yeast infection or thrash):
Rate all medications:
Check if taken:

Not at all
likely
to harm

Unlikely to
cause harm

Somewhat
likely to harm

Likely
to harm

Very
likely
to harm

[ ] Vaginal cream or

suppositories
(Monistat, Vagistat,
Femstat, Lotrim)

1

2
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3

4

5

[ ] Other medication –

1

2

3

4

5

specify: _________________________________________________________________

Nicotine Replacement Therapy (for smoking cessation):
Rate all medications:
Check if taken:

Not at all
likely
to harm

Unlikely to
cause harm

Somewhat
likely to harm

Likely
to harm

Very
likely
to harm

[ ] Nicotine gum, spray

or inhaler

1

2

3

4

5

[ ] Nicotine patch

1

2

3

4

5

[ ] Other medication –

1

2

3

4

5

specify: _________________________________________________________________
Other over-the-counter medications you have taken while pregnant:
Rate all medications:
Check if taken:

[ ] Other medication –

Not at all
likely
to harm

1

Unlikely to
cause harm

Somewhat
likely to harm

Likely
to harm

Very
likely
to harm

2

3

4

5

2

3

4

5

2

3

4

5

specify: ___________________
[ ] Other medication –

1

specify: __________________
[ ] Other medication –

1

specify: __________________
50. If you took prescription medications regularly before you got pregnant, did you
change the use of these medications when you realized you are pregnant?
[ ] Did not take prescription medications regularly before pregnancy
[ ] Discontinued the use upon recognition of pregnancy.
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Medication_________________
[ ] Decreased the use (dose or frequency).
Medication: _________________
[ ] Increased the use.
Medication: _________________
[ ] Stayed the same, continued without any change.
Medication: ___________________
50a. If you changed the use of a medication upon recognition of pregnancy, why?
[ ] Provider recommendation
[ ] Family or friend suggestion
[ ] Self-initiated
[ ] Financial constraints
[ ] Other: _______________________________________________________
Now I‟m going to ask you about your thoughts about medication use during pregnancy in
general. Please check the answer you think is the most appropriate for each question.
51. If a woman plans a pregnancy or finds out that she is currently pregnant, she should:
[ ] Stop taking all medications immediately to protect the baby
[ ] Continue taking only those medications that are absolutely necessary and

check with her doctor to see if the medications are safe for the baby
[ ] Continue taking necessary medications but reduce the dose or the number of
days you take them to limit the amount that gets to the baby
[ ] Continue with all medications as needed since medications are safe for the
baby
52. When a woman uses medications regularly during pregnancy, how often can
medications
cause birth defects?
[]
Never

[]
Sometimes

[]
Often

[]
Very Often
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[]
Always

53. Which statement best describes your view about women drinking alcohol during
pregnancy?
[ ] Pregnant women should abstain from drinking any alcohol (even small

amounts) during pregnancy.
[ ] It is OK for a woman to have an occasional drink during pregnancy
as long as it is not more often than once a week.
[ ] It is OK for a woman to have an occasional drink during pregnancy
as long as it is not more often than one drink per day.
[ ] It is OK for a woman to have an occasional drink during pregnancy
as long as it is not more often than two drinks per day.
[ ] It is OK for a woman to drink during pregnancy as long as she does not drink

hard liquor (i.e., vodka, whiskey, brandy) but only drinks wine or beer.
54. During your current pregnancy, have you ever asked anyone about the safety of
medications you are taking for your baby?
[ ] Yes

[ ] No

54a. If yes, check any individuals who you have asked a question about the safety of
any medications for your baby: (Check all that apply to you)
[ ] Your primary care doctor or provider
[ ] Your OB/GYN doctor or midwife
[ ] A pharmacist
[ ] A member of your family, spouse
[ ] A friend, partner
[ ] Other – specify: ______________________________________________________
[ ] Any other heath care provider

55. Please check any sources below in which you have looked for information about the
safety of medications for your baby? (Check all that apply to you)
[ ] I have never looked at any of these sources about the safety of medications for my
baby
[ ] An internet web site(s). Specify: ________________________________________
[ ] A book.
[ ] A magazine
[ ] Pregnancy information telephone service/hotline (i.e., OTIS, Nurse Advisory Line)
[ ] Other – Specify:___________________________________________________
[ ] I have not had any questions about the safety of medications for my baby and have not
looked at any of these sources.
[ ] Clinic pamphlet or brochure

114

56. NOTES/COMMENTS:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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APPENDIX 3: SAS-MACRO USED FOR ESTIMATING PREVALENCEADJUSTED AND BIAS-ADJUSTED KAPPA (PABAK)
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/*GENEARTE A WINDOW TO INPUT RATING RESPONSES*/
%window kap color=white
#2 @33 'Rater Agreement' attr=(highlight,underline) color=blue
#4 @34 '2 Raters Only' attr=highlight color=blue
#7 @19 'Enter the counts a, b, c, and d in the table below:' attr=highlight
color=blue #8 @25 '(Use the TAB key to jump to next cell)' color=blue
#11 @16 ' RATER B '
#12 @38 'YES' attr = highlight @68 'NO' attr = highlight
#13 @18 '_____________________________________________________________'
#15 @15 'YES' attr = highlight @22 'Cell A' @34 a 10 attr = underline
required=yes
#15 @52 'Cell B' @64 b 10 attr = underline required=yes
#16
@3
'RATER
A'
@18
'_____________________________________________________________'
#18 @16 'NO' attr = highlight @22 'Cell C' @34 c 10 attr = underline
required=yes
#18 @52 'Cell D' @64 d 10 attr = underline required=yes
#19 @18 '_____________________________________________________________'
#23 @22 'YES or NO indicate the dichotomous responses for each rater'
#30 @33 'Press ENTER to continue' attr=highlight ;
%macro def ;
%let a = ;
%let b = ;
%let c = ;
%let d = ;
%display kap ;
%mend def ;
%def ;data one;
set two;
if mix(var1, var2) > 0 then do;
/*DEFINE FORMATS*/
proc format ;
value rating
0 = "poor"
1 = "slight"
2 = "fair"
3 = "moderate"
4 = "substantial"
5 = "almost perfect"
6 = "cannot calculate kappa"
;
value rs
1 = "yes"
2 = "no"
;
run ;
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/*CALCULATE THE MEASURES OF AGREEMENT*/
data calcs ;
a = &a ;
b = &b ;
c = &c ;
d = &d ;
N = a+b+c+d ;
po =
pe =
ppos
pneg

(a+d)/N ;
((a+c)*(a+b)+(b+d)*(c+d))/N**2 ;
= (2*a)/(N+a-d) ;
= (2*d)/(N-a+d) ;

pi = (a-d)/N ;
bi = (b-c)/N ;
pabak = 2*po-1 ;
kappa = (po-pe)/(1-pe) ;
q = ((a/N)*(1-(((a+b)/N)+((a+c)/N))*(1-kappa))**2)+((d/N)*
(1-(((c+d)/N)+((b+d)/N))*(1-kappa))**2);
r = ((1-kappa)**2)*((b/N)*(((a+c)/N)+((c+d)/N))**2+(c/N)*
(((b+d)/N)+((a+b)/N))**2) ;
s = (kappa - pe*(1-kappa))**2 ;
*Asymptotic standard error ;
se_kappa = sqrt((q+r-s)/(N*(1-pe)**2)) ;
LL_95_CI = kappa-1.96*se_kappa ;
if LL_95_CI < -1.00 then LL_95_CI = -1.00 ;
UL_95_CI = kappa+1.96*se_kappa;
if UL_95_CI > 1 then UL_95_CI = 1.00 ;
se_kappa_null =sqrt((1/(N*(1-pe)**2))*(pe+(pe**2)((((a+b)/N)*((a+c)/N)*(((a+b)/N)+((a+c)/N))+((c+d)/N)*((b+d)/N)*(((c+d)/
N)+((b+d)/N)))))) ;
z = kappa/se_kappa_null ;
p = 1 - cdf('Normal',z,0,1) ;
label se_kappa = "Kappa Std. Error" ;
label LL_95_CI = "95% CI Lower Limit" ;
label UL_95_CI = "95% CI Upper Limit" ;
label se_kappa_null = "Kappa Std. Error (Under Ho)" ;
label z = "Z (Under Ho:Kap=0)" ;
label p = "One sided p-value (Under Ho:Kap=0)" ;
label po = "Observed Agreement (Po)" ;
label pe = "Expected Agreement (Pe)" ;
label ppos = "Positive Agreement (Ppos)" ;
label pneg = "Negative Agreement (Pneg)" ;
label pi = "Prevalence Index" ;
label bi = "Bias Index" ;
label kappa = "Kappa" ;
label pabak = "PABAK" ;
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strength = 0 ;
if kappa gt 0.00 and kappa
if kappa gt 0.20 and kappa
if kappa gt 0.40 and kappa
if kappa gt 0.60 and kappa
if kappa gt 0.80 and kappa
if kappa = . then strength
format strength rating. ;
label strength = "Strength
run ;

le 0.20
le 0.40
le 0.60
le 0.80
le 1.00
= 6 ;

then
then
then
then
then

strength
strength
strength
strength
strength

=
=
=
=
=

1
2
3
4
5

;
;
;
;
;

of Agreement" ;

proc print data = calcs label noobs ;
var kappa strength se_kappa LL_95_CI UL_95_CI se_kappa_null z p po pe ppos pneg
pi bi pabak ;
format po pe ppos pneg pi bi kappa se_kappa LL_95_CI UL_95_CI se_kappa_null p
pabak 6.4 z 4.2 ;
run ;
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